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Abstract 
Cellular, structural and functional characterization of mitochondrial Phosphoglycerate 
Mutase 5 
by 
Karen P. Ruiz 
This thesis examines multiple facets of the mitochondrial phosphatase Phosphoglycerate 
Mutase Family Member 5 (PGAM5), including its structure, function and mechanism of 
activation.  The Phosphoglycerate mutase family, titled for its namesake phosphoglycerate Mutase 
(PGAM), is a family of enzymes able to catalyze the transfer of a phosphate group from 3-
phosphoglycerate to 2-phosphoglycerate.  Despite a conserved catalytic core and its classification 
into the PGAM family, PGAM5 lacks any detectable phosphoglycerate mutase activity and 
paradoxically possesses phosphatase activity. 
PGAM5 is a mitochondrially localized serine, threonine and histidine phosphatase that is 
responsible for dephosphorylation of a wide variety of cytosolic protein substrates and has been 
identified as an interacting partner of multiple mitochondrial proteins. This mitochondrially-
tethered protein has been implicated in progression of apoptosis, necrosis and mitophagy where it 
has been shown to promote cell death in response to oxidative stress or mitochondrial damage. In 
addition to its role in contributing to mitochondrial destruction and cell death, PGAM5 has been 
implicated in the regulation of mitochondrial fission. PGAM5’s exact switch from a possible 
mitochondrial remodeler to a harbinger of death is still unknown, though preliminary data suggests 
 vii 
it may be tied to its cleavage and subsequent migration from the inner mitochondrial membrane 
(IMM) space to the cytosol. 
When we embarked on this project in the Jura lab, the mechanism for regulation of 
PGAM5’s phosphatase activity was poorly understood, and as a result, the tools for understanding 
the biological functions of PGAM5 or manipulating its activity did not exist. Using a wide variety 
of techniques, among these X-ray crystallography, electron cryo-microscopy, super-resolution 
microscopy and activity assays, we have observed PGAM5 is able to form higher order filaments 
in solution and in cells and succeeded in dissecting the dodecamer that comprises these rings and 
leads to PGAM5’s activation as a phosphatase. 
The first chapter of this thesis contains a brief introduction to PGAM5, including 
background information on the histidine phosphatase superfamily, of which the PGAM family of 
proteins is classified, the PGAM family itself and PGAM5’s diverse roles in the cell. The second 
chapter of this thesis focuses on exploring the way in which PGAM5’s phosphatase activity is 
regulated. In this chapter, we explore PGAM5’s ability to form higher order structures, dissect 
these structures and unravel PGAM5’s activation as a phosphatase. The third chapter focuses on 
our work to employ our newfound structural knowledge of PGAM5 in an effort to identify, test 
and optimize novel PGAM5 activators and inhibitors.   
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1.1 Phosphatases 
A brief history of phosphatases  
Phosphorylation, a powerful reversible post-translational modification of proteins, lipids 
and carbohydrates that governs signal propagation, exists in a delicate balance maintained by 
opposing kinases and phosphatases. Eukaryotic protein phosphorylation, well-established on 
serine, threonine, tyrosine residues and most recently identified on histidine residues, allows for 
the rapid, efficient control of a myriad of cellular processes. Dysregulation or dysfunction of either 
of these enzymes underlies many human diseases.  
Despite performing equally important but opposite reactions, there exists a large difference 
in the number of eukaryotic kinases and phosphatases, their evolution and regulation, and 
ultimately, our knowledge and understanding of these two groups of proteins. With at least 550 
known protein kinases, this family of proteins makes up a large percent of the human genome. 
While it is estimated that at least 200 phosphatases exist, a definitive number remains elusive; this 
numerical discrepancy between these families was initially interpreted to suggest phosphatases 
lacked substrate specificity and may less tightly regulated1. Further overarching distinctions 
separate these two groups that perform antithetical functions; while the structures of protein 
kinases and the basic mechanistic principles for their activation are generally conserved2, protein 
phosphatases are more difficult to categorize using unifying criteria. This is due in large part to 
the fact that phosphatase activity is associated with a wide variety of protein folds and catalytic 
mechanisms, many of which have additional hydrolase activity or are found in nonenzymatic 
proteins; this is in sharp contrast to protein kinases, which have similar three dimensional 
structures whose catalytic domains arise predominantly from a single protein structural fold3, and 
which adopt similar structures when active4. While significant progress has been made in 
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furthering our understanding of kinases, catalytically and structurally, our collective understanding 
of phosphatases is lacking.  
 
Phosphatases: classical and atypical 
Classical protein phosphatases have been categorized historically into two broad classes 
relative to their substrates into as (i) protein serine/ threonine phosphatases (PSPs), (ii) protein 
tyrosine phosphatases (PTPs) or (iii) dual-specificity phosphatases (DUSPs)5. These three broad 
groups have been further subclassified into 21 distinct families within their classes based on their 
chemical structures and have been shown to be able to adopt at least 10 distinct possible protein 
folds3. Despite best efforts to identify and organize these proteins, however, their study has been 
laborious and slow. Several factors have made studies on phosphatases especially challenging, 
among these: (i) the technical difficulty of generating phosphorylated substrate to probe for 
phosphatase activity, (ii) the transient nature of phosphatase and substrate interactions, (iii) the 
diversity in possible protein folds and (iv) the diversity of phosphatase active sites, which impedes 
general inhibitor design6. Further complicating their study, many phosphatases have been recently 
identified which do not conform to these classical phosphatase families due to differences in their 
structural and enzymatic features.  These increasing numbers of atypical protein phosphatases have 
been implicated in the regulation of various critical physiological processes and present a shift in 
our understanding of these enzymes7. Among these atypical phosphatases, phosphoglycerate 
mutase family member 5 (PGAM5), a member of the Histidine phosphatase superfamily, has 
emerged as a multifaceted regulator of cell death, mitochondrial homeostasis and cell signaling. 
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Histidine phosphatase superfamily 
While functionally diverse, the histidine phosphatase superfamily share a conserved 
catalytic core with a key histidine residue. During the course of the reaction, this essential histidine 
residue functions as a phosho-acceptor and becomes phosphorylated. The founding member of this 
superfamily is Phosphoglycerate Mutase, was identified as early as 19358, and the family has 
grown since to encapsulate two large branches, the majority of which are phosphatases involved a 
wide variety of regulatory roles. Perhaps ironically, the vast majority of this superfamily of 
enzymes has been found to possess phosphatase activity, while its founding member has become 
an anomaly with its mutase function9.    
The larger first branch of the family, clade-1, is functionally and sequentially diverse. 
Branch 1 has been identified as containing the PGAM family and various hydrolases and has been 
observed to have significant sequence diversity between members of the branch. In addition to 
functional and sequential diversity, the first branch of the family has been found to exist in a variety 
of cellular localizations, from cytoplasm to nucleus.   
The second branch of the family, clade-2 is made up predominantly of acid phosphatases, 
proteins that hydrolyze phosphate esters at low pH, and phytases, proteins able to catalyze the 
hydrolysis of phytate to myo-inositol and inorganic phosphate. Despite a greater conservation in 
the enzyme type that characterizes branch 2 of the histidine phosphatase superfamily, branch 2 
also possesses a high degree of sequence diversity. It has been found that the majority of branch 2 
family proteins exist in various subcellular locations such as the endoplasmic reticulum or cell 
membrane while others have been found to be secreted; key to branch 2 proteins is their ability to 
enter the secretory pathway.  
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Despite a conserved catalytic core histidine residue, the two branches of the family share 
little sequence similarity to themselves and each other, making proper identification and 
organization of the families that comprise this family difficult. This difference between the 
branches is further exemplified in their structural differences.  
Despite vast differences in protein sizes, roles and subcellular location, the catalytic 
mechanism for the members of the histidine phosphatase superfamily is conserved. Four largely 
invariant residues make up the catalytic core, three of which make up the characteristic RHG motif 
in the core. While the catalytic histidine is phosphorylated during the course of the reaction, the 
other three residues making up the RHG motif are able to form the ‘phosphate pocket’ and are able 
to electrostatically interact with the phospho group prior to, during and after its interaction with 
the central histidine during catalysis9.  
 
The Phosphoglycerate Mutase family 
The phosphoglycerate mutase family, categorized in branch 1 of the histidine phosphatase 
superfamily, contains various metabolic enzymes that possess mutase activity on small molecule 
substrates. PGAM enzymes have been observed to typically function as phosphotransferases or 
phosphohydrolases of small metabolites10, have recently been assigned to the histidine 
phosphatase superfamily9 and were initially classified by their shared catalytic PGAM domain. 
The most well-characterized member of this family is its namesake, phosphoglycerate mutase, 
which is able to convert 3-phosphoglycerate (3PG) to 2-phosphoglycerate (2PG) during step 8 of 
glycolysis, where it is able to function as an isomerase. Many other members of this PGAM family 
have been observed to function as mutases in metabolic pathways where they serve to catalyze the 
transfer of a phosphate group from one position to another on the same substrate through the use 
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of a conserved phosphohistidine intermediate, a function which is dependent on the conserved 
histidine residue tucked in the PGAM domain. Interestingly enough, many of these family 
members have also been observed to for dimers11. 
Despite this family’s placement in the histidine phosphatase superfamily and a its 
conservation of the central histidine residue that comprises the active site of these enzymes, many 
of these family members, with three exceptions, possess mutase activity. Despite the conservation 
of this core PGAM domain across the various members of the PGAM family of enzymes, three 
members of the PGAM family: Sts-1, Sts-2 and PGAM5, have been shown to lack observable 
mutase activity and instead been observed to dephosphorylate protein substrates. Although lacking 
any detectable mutase activity, PGAM5 was initially categorized as a member of the 
Phosphoglycerate Mutase (PGAM) family of enzymes that share the conserved PGAM domain 
despite lacking mutase activity. Similar to PGAM5, The Sts phosphatases have been observed to 
diverge from the rest of the PGAM family catalytically. Sts 1 and sts2 have been shown to be 
specific towards phosphorylated tyrosine residues12, while PGAM5 was initially identified as 
possessing serine/ threonine phosphatase activity13. Most recently, PGAM5 has been shown to 
possess histidine phosphatase activity through its ability to dephosphorylate the catalytic histidine 
on cytosolic nucleoside diphosphatase kinase B (NDPK-B)14 and remains one of the most 
perplexing members of the PGAM family.  
 
1.2 Phosphoglycerate Mutase Family Member 5 
Domain architecture of PGAM5 and its localization 
 Classified into the PGAM family, PGAM5 retains the canonical PGAM domain that 
characterizes this family of proteins, however, presents remarkable other differences that make it 
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novel and unique, among these its localization and mechanism of activation. PGAM5 is targeted 
to the mitochondria by an N-terminal mitochondrial targeting sequence (MS).  The N-terminal 
mitochondrial targeting signal that anchors PGAM5 to the mitochondrial membrane is followed 
by a linker domain and the PGAM phosphatase domain. Initial studies by Wilkins and colleagues 
demonstrated that the linker domain greatly potentiates activity of the recombinant PGAM5 and 
identified a region within the linker domain responsible for the observed enhancement15. This 
region, termed the multimerization motif, also promoted higher-order oligomerization of the 
recombinant PGAM5 construct, which was composed of the linker and phosphatase domains. The 
importance of this motif is underscored by its conservation  
In the absence of the linker domain, PGAM5 was unable to oligomerize and displayed 
minimal phosphatase activity. This work was seminal, as it functionally linked PGAM5’s activity 
as a phosphatase to its ability to form an unknown oligomer. Within the mitochondria, PGAM5’s 
exact localization is still debated. There is some evidence for PGAM5 localization to the Inner 
Mitochondrial Membrane (IMM)16,17, while other data suggests PGAM5 can be found on the Outer 
Mitochondrial membrane (OMM) with its phosphatase domain accessible from the cytosol18. 
Localization of PGAM5 to the inner mitochondrial membranes is supported by the observation 
that PGAM5 is cleaved by at least two IMM-resident proteases: presenilins-associated rhomboid-
like protein (PARL)16 and the metalloprotease OMA119, generating a fragment of PGAM5 that 
lacks the transmembrane targeting sequence. PGAM5 cleavage occurs under conditions of 
mitochondrial stress, which is triggered either by the loss of mitochondrial membrane potential 
(Dym) upon treatment with carbonyl cyanide m-chlorophenyl hydrazine (CCCP)16 or by inducers 
of apoptosis, such as staurosporin (STS) or actiomycin D20,21. Other studies have shown that 
following cleavage, a fraction of PGAM5 is released to the cytosol to engage in a number of 
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signaling functions16,20-22. Thus, it is possible that both localization patterns of PGAM5 are correct, 
as current data suggests that PGAM5’s localization is dynamic and stress-responsive.  
 
The various roles of PGAM5 in the cell 
PGAM5 contributes to homeostasis through regulation of mitochondrial dynamics, 
respiration, mitophagy quality control and cell survival. PGAM5 was initially identified as a 
binding partner of KEAP1 and Bcl-xL23. As an adaptor protein for the Cul3-dependent E3 
ubiquitin ligase complex, KEAP1 serves as a major sensor of oxidative stress by controlling 
ubiquitination and degradation of the NRF2 transcription factor. PGAM5 was shown to form a 
ternary complex with KEAP1 and NRF2 on the OMM, suppressing KEAP1 activity18. The 
functional role of this complex has also been linked to the regulation of Miro2, a mitochondrial 
GTPase that regulates retrograde transport of the mitochondria along microtubules24.  
PGAM5 also binds to the PTEN-induced kinase (PINK1), an important regulator of 
mitochondrial quality control17,25. PINK1 accumulates and dimerizes on damaged mitochondrial 
outer membranes, resulting in the recruitment of PARKIN and downstream initiation of 
mitophagy26-29. Although genetic studies in flies suggest a negative effect of PGAM5 on PINK1 
signaling25, studies in mice provide evidence that overwhelmingly supports the opposite effect17. 
The data in mice shows PGAM5 stabilizes PINK1 and promotes mitophagy as a protective 
measure against neuronal degeneration. Similar to the effect of PINK1 loss or kinase inactivating 
mutations on promoting neurodegeneration30-33, loss of PGAM5 results in a Parkinson’s disease-
like phenotype caused by degeneration of dopaminergic neurons17.  
The involvement of PGAM5 in promoting mitophagy is corroborated by other studies. In 
response to hypoxia or loss of mitochondrial membrane potential, PGAM5 binds and 
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dephosphorylates FUNDC1, which promotes L3 binding and recruitment of autophagosomes to 
mitochondria34. This function of PGAM5 is negatively regulated through binding of BCL2L1, 
which inhibits PGAM5-dependent dephosphorylation of FUNDC1 and opposes mitophagy35.  
It has been observed that genetic knockout of PGAM5 in mice leads to a more severe 
Parkinson’s disease-like phenotype than PINK1 knockout, suggesting that independent from the 
PINK1/ Parkin pathway, other functions of PGAM5 might be important for dopaminergic neuron 
survival. Regulation of mitochondrial motility through the stabilization of the KEAP1/ NRF2/ 
PGAM5 ternary complex is suggested to be one of these functions24. Other functions include a 
role for PGAM5 in metabolism. Genetic ablation of PGAM5 in the mouse causes resistance to 
high fat diet induced obesity linked to enhanced lipid uptake and utilization in the brown adipose 
tissue36, as well as slight decrease in basal body weight37. These effects might be the result of a 
poorly understood role of PGAM5 in the regulation of mitochondrial morphology. PGAM5 
overexpression results in visibly altered mitochondrial dynamics, such as perinuclear aggregation 
and fragmentation of the mitochondria18. Drastic changes in mitochondrial dynamics, such as rapid 
mitochondrial fission in brown adipocytes in response to adrenergic stimulation, was shown to 
promote energy expenditure38. More recent studies shown that PGAM5 is essential for the 
induction of FOXO-dependent transcription in response to the mitochondrial unfolded protein 
response in which PGAM5 exerts a protective effect on cells and contributes to organismal 
longevity39.  
Perhaps the least understood PGAM5 function is its role in the regulation of cell 
death21,40,41. In necroptosis, initiated by Tumor Necrosis Factor alpha (TNFa) and involving 
kinases RIP1, RIP3 and MLKL, PGAM5 was suggested to be a part of a RIP1 and RIP3 kinase 
complex promoting cell death40. Upon necrosis induction, PGAM5 was first proposed to recruit 
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and dephosphorylate the mitochondrial fission factor, DRP1, resulting in mitochondrial 
fragmentation, a necessary step to necroptosis40. However, the PGAM5/ DRP1 axis was later 
shown to be dispensable for TNFa-induced necroptosis by several other studies42-44, with the 
exception of its function in hepatocytes where ConA-induced hepatic necrosis involves abnormal 
mitochondrial fission through the Drp1/ PGAM5 pathway45. In a different study, PGAM5 was also 
shown to be irrelevant to necroptosis, instead being involved in inflammation through promotion 
of inflammasomes and caspase 1 activation in macrophages37. PGAM5 was also shown to sensitize 
cells to apoptosis through binding of XIAP, a member of an IAP family of caspase inhibitors, and 
prevent XIAP from binding caspases21. This function of PGAM5 is linked to the release of its 
cleaved form into the cytosol. Adding to the complexity of the roles PGAM5 plays in regulating 
cell death, a recent study has shown that PGAM5 protects cells from necroptosis through its 
positive effect on PINK1-dependent mitophagy46. PGAM5’s involvement in such a wide array of 
cellular processes, combined with its complex self-regulation and interesting cellular make it a 
compelling subject of study.   
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Chapter 2: Functional role of PGAM5 multimeric assemblies and their polymerization into 
filaments 
 
This chapter contains a reprint of “Functional role of PGAM5 multimeric assemblies and their 
polymerization into filaments”, published in Nature Communications on January 31, 2019.  
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purified each of the protein constructs, performed cell-based confocal, SIM and STED imaging, 
X-ray crystallography, titration experiments and analysis and contributed to paper writing. Tarjani 
M. Thaker acquired negative stain images, conducted Cryo-EM data acquisition and processing, 
performed Blue Native-PAGE experiments, and contributed to developing the project and paper 
writing. Christopher Agnew helped with X-ray crystallography data acquisition, processing and 
deposition. Maria Ingaramo assisted with STED training and data acquisition. Raphael Trenker 
performed kinetics experiments. Natalia Jura contributed to the project development, data analysis 
and paper writing.  
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2.1 ABSTRACT  
 PGAM5 is a mitochondrial protein phosphatase whose genetic ablation in mice results in 
mitochondria-related disorders, including neurodegeneration. Functions of PGAM5 include 
regulation of mitophagy, cell death, metabolism and aging. However, mechanisms regulating 
PGAM5 activation and signaling are poorly understood. Using electron cryo-microscopy, we 
showed that PGAM5 forms dodecamers in solution. We also present a crystal structure of PGAM5 
that reveals the determinants of dodecamer formation. Furthermore, we observed PGAM5 
dodecamer assembly into filaments both in vitro and in cells. We found that PGAM5 
oligomerization into a dodecamer is not only essential for catalytic activation, but this form also 
plays a structural role on mitochondrial membranes, which is independent of phosphatase activity. 
Together, these findings suggest that modulation of the oligomerization of PGAM5 may be a 
regulatory switch of potential therapeutic interest. 
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2.2 INTRODUCTION 
 Phosphoglycerate mutase family member 5 (PGAM5) is an atypical protein phosphatase 
implicated in a number of functions within mitochondria, including organelle homeostasis, 
mitophagy and cell death. As a member of the PGAM histidine phosphatase superfamily, PGAM5 
has the conserved PGAM domain1. However, unlike most PGAM enzymes, which are 
phosphotransferases or phosphohydrolases of small metabolites, PGAM5 dephosphorylates 
protein substrates2, targeting phosphorylated serine, threonine, and histidine residues3,4. PGAM5 
contains an N-terminal mitochondrial targeting sequence (MTS), which also serves as a membrane 
anchor. Experimental evidence supports PGAM5 localization to the outer mitochondrial 
membrane (OMM), where its phosphatase domain is accessible from both the cytosol5 and the 
inner mitochondrial membrane (IMM)6,7. In response to loss of mitochondrial membrane potential 
(Dym)6 or apoptosis8,9, PGAM5 undergoes cleavage by two IMM-resident proteases, presenilin-
associated rhomboid-like protein (PARL)6 and the metalloprotease OMA110, generating a 
fragment of PGAM5 missing the MTS (Fig. 2.1a) that can be partially released into the 
cytosol6,8,9,11. Thus, the localization of PGAM5 seems dynamic and stress responsive. 
 PGAM5 has been linked to mitochondrial homeostasis and cell death through the 
regulation of mitochondrial dynamics, respiration and mitophagic quality control. Interaction 
partners of PGAM5 include KEAP1, an adaptor protein for the Cul3-dependent E3 ubiquitin ligase 
complex, and Bcl-XL, an anti-apoptotic protein12. By inhibiting KEAP1 activity5, PGAM5 
promotes retrograde transport of mitochondria along microtubules by the GTPase Miro213. 
PGAM5 also regulates levels of PTEN-induced kinase 1 (PINK1), a guardian of mitochondrial 
quality control7,14, which upon mitochondrial damage accumulates on the cytosolic surface of 
mitochondria to recruit Parkin and initiate mitophagy15-18. In mice, PGAM5 stabilizes PINK1 and 
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promotes mitophagy to protect against neuronal degeneration7, whereas in flies PGAM5 
negatively regulates PINK114. In response to hypoxia or loss of mitochondrial membrane potential, 
PGAM5 binds and dephosphorylates FUNDC1, promoting recruitment of autophagosomes to 
mitochondria19, consistent with PGAM5’s role in promotion of mitophagy. Notably, PGAM5 
knockout in mice leads to a more severe Parkinson’s disease-like phenotype than observed for 
PINK1 knockout, suggesting that PGAM5 has multiple functions that support dopaminergic 
neuron survival7,20-23.  
The role of PGAM5 in cell death is poorly understood 9,24,25. In necroptosis, initiated by 
Tumor Necrosis Factor alpha (TNFa), PGAM5 may be a part of a complex with the kinases RIP1 
and RIP3 that promotes cell death through dephosphorylation of the mitochondrial fission factor 
DRP124. However, the PGAM5/DRP1 axis is dispensable for TNFa-induced necroptosis in many 
cells and conditions26-29, except for ConA-induced hepatic necrosis30. Other studies link PGAM5 
to apoptosis through sequestration of a caspase inhibitor, XIAP E3 ubiquitin ligase9. During 
apoptosis, PGAM5 also contributes to mitochondrial recruitment of Bax and to DRP1 
dephosphorylation, possibly be engaging them in a heteromeric complex31. Most recently, PGAM5 
was shown to protect cells from necroptosis through its positive effect on PINK1-dependent 
mitophagy32. 
 Biochemical and structural studies elude to an elaborate mechanism by which many 
functions of PGAM5 might be controlled. Between the MTS and phosphatase domain, PGAM5 
contains a linker domain (Fig. 2.1a) with a centrally located “multimerization motif” that 
potentiates PGAM5 activity33. The multimerization motif also promotes higher-order 
oligomerization of PGAM533. A crystal structure of PGAM5 containing the linker and phosphatase 
domains showed that the multimerization motif stabilizes a catalytically active conformation of 
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the enzyme34. The structure also revealed a dodecameric, ring-shaped organization of the 
phosphatase domain in the crystal lattice34, of unknown physiological relevance. 
 Here, we provide evidence that oligomerization is essential for PGAM5 catalysis and 
present a new crystal structure of the PGAM5 ring demonstrating the sufficiency of the 
multimerization motif for PGAM5 dodecamer formation. We also discover that PGAM5 can adopt 
different oligomeric states in solution, including filamentous structures composed of stacked 
dodecameric rings that can form both in vitro and in cells. Lastly, we find that PGAM5 
oligomerization exerts a structural effect on mitochondrial membranes that is independent of its 
phosphatase activity. Taken together, we propose that the functions of this atypical phosphatase 
are regulated through both catalytic and non-catalytic mechanisms.   
 
  
 22 
2.3 RESULTS 
Linker domain induces filamentation of the PGAM5 phosphatase  
To understand the mechanism of oligomerization-dependent activation of PGAM5, we 
purified a truncated form of PGAM5 (D48 PGAM5), previously characterized as a stable and fully 
active construct, which includes the multimerization motif (residues 58 – 63) (Fig. 2.1a)33. We 
focused on the form of PGAM5, known as PGAM5L, that has an intact PGAM domain formed by 
residues 98-289. D48 PGAM5 resolved as two distinct peaks during size exclusion 
chromatography (Fig. 2.1b). The later peak was consistent with the profile expected for a dimeric 
complex of PGAM5, similar to the elution observed for the isolated phosphatase domain (D90 
PGAM5)33 (Fig. 2.1b). The earlier peak, however, was consistent with a larger oligomer that has 
been observed in biochemical preparations of a comparable construct, D54 PGAM533,34.   
Analysis of both chromatogram peaks using negative-stain electron microscopy (EM) 
revealed the presence of spontaneously formed filaments of several hundred nanometers in the 
earlier peak. These filaments were not observed in purified samples of PGAM5 dimers (D48 later 
peak or D90 PGAM5) (Fig. 2.1c). Filaments were comprised of a repeating unit with an occasional 
shift in register along the length of the filament. In addition, singular ring-like particles frequently 
decorated the ends of the filaments in an orientation perpendicular to the filament axis. We 
hypothesized that the filaments are comprised of individual rings, with the lumen of the ring 
forming the interior of the filament. The lack of isolated rings within either sample suggests that 
PGAM5 oligomerization into filaments is a cooperative process.   
The presence of rings and their potential role as the building blocks of PGAM5 filaments 
was intriguing, especially in light of a recent crystal structure of ∆54 PGAM5, which revealed a 
ring-like oligomer through lattice interactions between 12 copies of PGAM5 (PDB: 5MUF)34. ∆48  
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Fig. 2.1: ∆48 PGAM5 forms tubular filaments in solution composed of ring-like structures.  
a. Domain architecture of constructs used in this study. Full-length PGAM5 is comprised of a 
single transmembrane helix containing a mitochondrial targeting sequence (MTS), a linker domain 
including the regulatory multimerization motif (MM), and a C-terminal PGAM phosphatase 
domain. The native cleavage site between residues 24 and 25, cleaved by PARL6, is marked with 
a green arrow. b. Elution profiles for ∆48 and ∆90 PGAM5 constructs purified by size exclusion 
chromatography (SEC) using a Superose 6 column (GE Healthcare) in buffer containing 150 mM 
NaCl. The corresponding oligomeric states of each peak observed in the chromatograms are 
indicated. c. Representative EM micrographs of negatively-stained protein samples taken from 
fractions corresponding to the two distinct peaks observed in the ∆48 PGAM5 purification. d. SEC 
profiles for ∆48 PGAM5 in buffer containing 20 mM Tris-Cl pH 8.0, 500 µM TCEP, and NaCl at 
a final concentration of 150 mM, 300 mM, or 750 mM. EM micrographs of negatively-stained 
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samples of ∆48 PGAM5 taken directly from the primary peak observed during purification are 
shown, highlighting the decomposition of filaments into rings at increasing salt concentrations. 
Scale bars in (c) and (d) correspond to 50 nm, except for the inset in (c) in which the scale bar 
corresponds to 10 nm. 
 
PGAM5 filaments could be dissociated into rings by increasing the ionic strength during 
purification (Fig. 2.1d). With high concentrations of NaCl (>500 mM NaCl), we could enrich for 
discrete PGAM5 rings, enabling structural analyses on the ring-like ∆48 PGAM5 state in solution. 
 
 PGAM5 rings in solution and in a new crystal structure 
We assessed the molecular structure of ∆48 PGAM5 rings in solution by cryo-EM. Our 
data revealed a mixture of PGAM5 ring particles with dimensions consistent with the formation 
of single rings, a doublet of rings, and less frequently, partial doublets (Fig. 2.2). The particles 
adopted a preferred orientation in the vitreous layer that limited the number of side views necessary 
for complete 3D reconstruction. Thus, we performed 2D classification of the top view of the ∆48 
PGAM5 ring, visualized along the central symmetry axis, revealing features of PGAM5 at a 
resolution sufficient to analyze its organization (Fig. 2.3a). The solution structure of ∆48 PGAM5 
adopted C6 symmetry in which six phosphatase domain dimers form a ring. Comparison of the 
best 2D class of the ∆48 PGAM5 ring to a projection image of the crystallographic ring observed 
in the structure of ∆54 PGAM534 (filtered to 4.5 Å resolution) showed similar ring architectures 
(Fig. 2.3b). Despite slightly different dimensions, stemming from the crystallographic symmetry 
of the ∆54 PGAM5 structure (Fig. 2.4a-d), the overall similarity in ring architecture verified that 
the dodecameric assembly of PGAM5 in the crystalline lattice of the ∆54 PGAM5 structure also 
occurs in solution.  
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Fig. 2.2: Representative electron cryo-micrograph and 2D class averages of ∆48 PGAM5 
dodecamer side views. a. Representative raw micrograph image of ∆48 PGAM5, with a 
representative side view of a dodecamer doublet circled on the image. The scale bar in (a) 
corresponds to 50 nm. b. Approximately 8.3% of the total number of particles picked from 6,543 
micrographs corresponded to orientations other than the C6 symmetry ‘top’ view of the dodecamer 
and were subject to iterative rounds of 2D-classification into 9 classes as described in the methods 
section of the main text, revealing a single class in which the side view of a doublet of dodecamers 
stacked on the apparent planar face of the assembly (class 9 comprised of 542 particles) is 
observed. The scale bar in (b) corresponds to 5 nm. 
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Fig. 2.3: Architecture of the PGAM5 dodecameric ring in solution and in a new crystal 
structure. a. 2D class average of the predominant view of the ring assembly observed in cryo-EM 
micrographs of ∆48 PGAM5 reveals a dodecameric topology highly similar in architecture to (b). 
b. 2D projection image of the crystallographic ring observed in the crystal lattice of the ∆54 
PGAM5 dimer (PDB: 5MUF) limited to 4.5 Å resolution. c. Architecture and subunit arrangement 
of the dodecameric assembly observed in the crystal structure of the ∆90 PGAM5 H105A 
phosphatase domain crystallized in the presence of the peptide containing the multimerization 
motif (MM).  
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Fig. 2.4: Overview of dodecamer geometry in ∆90 PGAM5 H105A/MM compared to ∆54 
PGAM5. Comparison of crystal packing in the structures of a. ∆90 PGAM5 H105A/MM and b. 
∆54 PGAM5 (PDB: 5MUF). Molecules related by symmetry are colored the same in the respective 
lattices. c. Overlay of the dodecameric assemblies of ∆90 PGAM5 H105A/MM and ∆54 PGAM5, 
highlighting the differences in the geometry of the dodecamer lumen. d. Comparison of dodecamer 
dimensions in ∆90 PGAM5 H105A/MM (left panel) and ∆54 PGAM5 (right panel). e Differences 
in the dimerization interface mediated by the α3 helices of two adjacent phosphatase domains are 
highlighted in the structures of ∆54 PGAM5 (grey) and ∆90 PGAM5 H105A/MM colored using 
the same color scheme as shown in Fig. 2.2 (monomer 1 in cyan; monomer 2 in light blue). A 
detailed view of the interface and residues within the multimerization motifs in the monomer 1 in 
both structures are shown as stick representation in the panel on the right. 
 
 28 
 
In the D54 PGAM5 crystal structure, the linker domain is mostly disordered, except for a region 
corresponding to the multimerization motif34. Similarly, we could not clearly identify the linker 
domain in 2D classes of the D48 PGAM5 ring (Fig. 2.3a). These observations suggested that the 
interactions supported by the multimerization motif might be sufficient to drive oligomerization 
and activation of PGAM5. This model is supported by a crystal structure we determined for a 
shorter fragment of a catalytically dead PGAM5 phosphatase domain (D90 PGAM5 H105A), in 
complex with a peptide encompassing the multimerization motif (linker domain residues 54 – 67, 
denoted as MM) (Table 2.1, 2.3c). The asymmetric unit of the unit cell in our 2.6 Å resolution 
structure of ∆90 PGAM5 H105A/MM revealed organization of the phosphatase domain into a 
dodecameric ring, with the multimerization motif peptide positioned in the lumen of the ring at the 
base of each phosphatase domain (Fig. 2.3c). Hence, our structure demonstrates that the 
multimerization motif is sufficient to induce the formation of a dodecameric PGAM5 ring, even 
when presented in trans.  
 
The active conformation is independent of phosphate binding 
The dodecameric ring in the crystal structure of ∆90 PGAM5 H105A/MM has a central 6-fold 
symmetry axis that better matches the C6 symmetry of the 2D class of the ∆48 PGAM5 ring than 
the C2 symmetry of the ∆54 PGAM5 crystallographic dodecamer (Fig. 2.3b). The differences 
between the two ring geometries stem from a slight rotation of the PGAM5 phosphatase monomers 
at the a3 helical interface; whereas the dimer interface-flanking residues F244 and burying 
approximately 1050.5 Å2 through hydrophobic interactions is the same in both structures (Fig. 
2.4e). Despite the differences, the ordered b3-a3 catalytic loop (residues 172 – 193) indicated that 
the phosphatase domain in both structures is in the active conformation (Fig. 2.5a). A notable 
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difference between the ∆54 PGAM5 structure and the ∆90 PGAM5 H105A/MM structure 
occurred in the b1-a1 loop (residues 105 – 121). In the D54 PGAM5 structure, this loop is ordered, 
whereas it is missing in the ∆90 PGAM5 H105A/MM dodecamer. This difference could be due to 
the engagement of the β1-a1 loop in crystal contacts in the D54 PGAM5 structure, but not in the 
∆90 PGAM5 H105A/MM structure. 
Mutation of the catalytic histidine (H105) to alanine resulted in active-site arrangements in 
our ring structure of ∆90 PGAM5 resembling an active state described as the PO4 ‘on’ 
conformation in the ∆54 PGAM5 structure34 (Fig. 2.5b, left and right panels). In this on state, the 
H230 residue is positioned inward relative to its position in the structure of the inactive 
phosphatase domain alone (∆90 PGAM5 (PDB:3MXO); Fig. 2.5b, center panel). In the ∆54 
PGAM5 structure residue R152 adopts a vertical, rather than the planar position observed in the 
∆90 PGAM5 dimer structure34, forming cation-p–stacking interactions with Y108, and together 
with H230 and H105, coordinates an active site phosphate (Fig. 2.5b, right panel). In the ∆90 
PGAM5 H105A/MM structure, residues R152, Y108 and H230 adopt similar orientations, but in 
the absence of phosphate (Fig. 2.5b, left panel). The on state observed for ∆90 PGAM5 
H105A/MM in the absence of bound phosphate underscores the importance of ring assembly for 
stabilizing the active architecture of the catalytic site.  
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Table 2.1: Data collection and refinement statistics.  
 ∆90 PGAM5 H105A/MM ∆90 PGAM5 H105A 
Data collection   
PDB ID 6CNL 6CNI 
Space group P 21 21 21 P 21 21 21 
Cell dimensions   
    a, b, c (Å) 49.4, 242.5, 272.5 71.0, 72.0, 81.9 
    a, b, g (°)  90, 90, 90 90, 90, 90 
Resolution (Å) 48.6 – 2.6 (2.69 – 2.6) 41.0 – 1.7 (1.76 – 1.7) 
Rsym or Rmerge 19.8 (105.8) 7.5 (76.0) 
I / sI 7.2 (1.4) 21.8 (2.3) 
Completeness (%) 99.8 (99.9) 99.7 (97.5) 
Redundancy 5.0 (5.1) 12.1 (7.8) 
   
Refinement   
Resolution (Å) 48.6 – 2.6 (2.69 – 2.6) 41.0 – 1.7 (1.76 – 1.7) 
No. reflections 509,660 (51,383) 564,588 (35,185) 
Rwork / Rfree % 22.3/26.4 (30.9/33.6) 17.1/19.7 (25.9/31.3) 
No. atoms   
    Protein 18,643 2,893 
    Ligand/ion 31 16 
    Water 199 308 
B-factors   
    Protein 35.5 26.2 
    Ligand/ion 30.5 25.8 
    Water 31.8 37.4 
R.m.s. deviations   
    Bond lengths (Å) 0.004 0.007 
    Bond angles (°) 
Ramachandran plot % 
    Favored  
    Additional allowed 
0.8 
 
97.8 
2.2 
1.1 
 
99.4 
0.00 
Values in parentheses are for highest-resolution shell. 
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Fig. 2.5: Active site in the crystal structure of the ∆90 PGAM5 H105A phosphatase. a. The 
cartoon representation of the crystal structure of the ∆90 PGAM5 H105A phosphatase is shown 
using the same color assignment as in Fig. 2.3, with monomers 1 and 2 shown in cyan and light 
blue, respectively. The β1-α1 loops are colored in orange, the β3-α3 loops are colored in green, 
the α3-β4 loops are colored in red. The F244 residues in the constitutive dimer interface are colored 
in yellow. b. Detailed view of the residue positions in the active site in the crystal structure of the 
∆90 PGAM5 H105A phosphatase depicting the coordination of a phosphate ion (PO4 ‘on’). 
 
 
Chaikuad and colleagues suggested that capping of the active site by the b3-a3 loop positions 
active site residues in the catalytically competent state34. However, a crystal structure of D90 
PGAM5 H105A without the multimerization motif that we determined suggests otherwise (Table 
2.1, Fig. 2.6). In this structure, PGAM5 phosphatase formed a dimer analogous to the one 
previously observed in the structure of D90 PGAM5 wild type (PDB:3MXO). Although the crystal 
packing was identical in the two Δ90 PGAM5 structures, the active site residues of Δ90 PGAM5 
H105A adopted catalytically competent conformations (PO4 ‘on’) in the presence of a phosphate 
ion (Fig. 2.6b). The main difference between this dimer conformation and the apo ‘on’ state of the 
dodecameric ∆90 PGAM5 H105A/MM structure was a disordered b3-a3 loop in Δ90 PGAM5 
H105A. Thus, in the absence of discrete phosphatase domain interactions with the b3-a3 loop, the 
active architecture can be achieved, at least structurally, as long as a phosphate ion is coordinated.  
∆90 PGAM5 H105Aa
β3-α3 loop
β3-α3 loop’
α3-β4 loop’
α3-β4 loop
β1-α1 loop
F244
F244’
β1-α1 loop’
C’
C
N’
N
PO4 ‘on’
S106
S289
R288
R104
A231
β1-α1 loop 
R152 
‘vertical’
Y108
N232
  E177 ‘out’
β3-α3 loop
H230
A105
b
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Fig. 2.6: Key features of PGAM5 activation in the crystal structure of ∆90 PGAM5 
H015A/MM. a. The structures of ∆90 PGAM5 H105A with the multimerization motif (MM) 
added in trans (∆90 PGAM5 H105A/MM) (left panel) compared to the structures of ∆90 PGAM5 
(PDB: 3MXO) (middle panel) and ∆54 PGAM5 with the MM present in cis (PDB: 5MUF) (right 
panel). Monomers 1 and 2 are colored cyan and light blue, respectively, in all structures with their 
corresponding MM regions colored in teal (monomer 1 MM) and dark blue (monomer 2 MM) 
where present. The β1- α1 loop is indicated in orange, the β3-α3 loop is indicated in green, the α3-
β4 loop is indicated in red. The F244 residues in the central axis forming the dimer interface are 
indicated in yellow. b. Detailed view of the catalytic core in ∆90 PGAM5 H105A/MM (left), ∆90 
PGAM5 (middle), and ∆54 PGAM5 (right) highlighting interactions between active site residues 
and the phosphate ion (PO4). c-d. Comparison of the MM architecture (left panel) and the 
differences in interactions with the phosphatase domain (right panel) for (c) ∆90 PGAM5 
H105A/MM and (d) ∆54 PGAM5. 
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Altogether, these structures point to a remarkable plasticity of the PGAM5 catalytic center, which 
indicates that multiple structural elements coordinate for catalysis. 
We also observed a notable difference in the conformation of the C-terminal region of the 
multimerization motif between our ∆90 PGAM5 H105A/MM structure and the previously 
determined ∆54 PGAM5 structure34. Although an identical length of the linker is resolved in both, 
the improved resolution of the ∆90 PGAM5 H105A/MM structure and overall quality of the 
electron density map in the linker region revealed a register shift in which the positions of R64 and 
R65 in the ∆54 PGAM5 structure are occupied by R65 and E66 in the ∆90 PGAM5 H105A/MM 
structure, respectively (Fig. 2.5c,d; Fig. 2.4e, Fig. 2.7). In ∆90 PGAM5 H105A/MM, R64 is 
positioned directly in the center of a dimerization interface mediated by the a3 helices (Fig. 2.5c, 
right panel), expanding the network of interactions in this region. The guanidinium group of R64 
in monomer 1 is also involved in a previously unobserved cation p–stacking interaction in trans 
with the phenyl ring of Y198 of the adjacent monomer. Residue E199, previously described as 
hydrogen bonded to R64 of the adjacent monomer, now interacts with R65. In both structures, 
R214 hydrogen bonds in cis with D63, and R209 with the backbone carbonyl of Y198 in trans 
(Fig. 2.5c,d).  
 
Catalytic activation of PGAM5 requires dodecamer formation 
We further examined the role of dodecamer formation in the regulation of PGAM5 activity. 
In PGAM5 ring structures, each multimerization motif peptide interacts with three phosphatase 
domain monomers. An interaction with the central phosphatase subunit involves binding of the 
WDxxWD sequence of the multimerization motif. Two additional minor interactions engage N- 
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and C-terminal ends of the multimerization motif with two distinct dimer interfaces formed by the 
neighboring phosphatase domains (Fig. 2.8a). 
 
Fig. 2.7: Multimerization motif residue register and corresponding electron density. 
Differences in the electron density (2Fo-Fc maps contoured to 1σ), and subsequent amino acid 
assignment, of the multimerization motif region (residues 64 – 66) interacting with the phosphatase 
domain in a. ∆54 PGAM5 (PDB: 5MUF) and b. ∆90 PGAM5 H105A/MM. c. Stereo 
representation of the multimerization motif peptide (teal) associated with monomer 1 (cyan) in 
∆90 PGAM5 H105A/MM, with corresponding 2Fo-Fc electron density contoured to 1.0σ. 
 
 
We defined the first minor interaction as the F dimer interface because of the presence of a pair of 
centrally located F244 residues supporting the dimerization interface. We defined the second 
interaction as the a3 dimer interface, because it involves a phosphatase domain dimer that engages 
the a3 helices. We introduced the F244E mutation to disrupt the F dimer interface and Y198E or 
R65A mutations to disrupt the a3 dimer interface (Fig. 2.8b). We also generated an A4 mutant of 
PGAM5 in which residues WDxxWD of the multimerization motif are replaced by the AAxxAA 
sequence, which inactivates PGAM533.  
a b
R64
R65
E66A
HOH418
HOH401
∆54 PGAM5
R64
R65
E66
∆90 PGAM5 H105A/MM
c
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All four mutations affected D48 PGAM5 oligomerization (Fig. 2.8b,c). The F244E 
mutation had the most dramatic effect, shifting the entire population of D48 PGAM5 to a 
monomeric state. Likewise, the A4 mutant did not engage in higher-order oligomerization and, 
instead, preferentially formed dimers. Like the A4 mutant, both the Y198E and R65A mutants 
were predominantly or completely dimers. Because none of the A4, Y198E, or R65A mutations 
altered the F dimer interface, we predicted that their dimeric state is likely stabilized by the F244-
centered interface (Fig. 2.8a). These findings suggested that, although both the F dimer and a3 
dimer interfaces are important for ring formation, only the F244-mediated dimerization occurs in 
the absence of dodecamer formation.  
We determined the catalytic activity of the PGAM5 interface mutants, including the H105A 
mutant as a negative control, by measuring the rate of PGAM5-mediated dephosphorylation of a 
phospho-ASK1 substrate peptide (Table 2.2). Like the A4 mutant, the monomerizing F244E 
mutation also resulted in the loss of phosphatase activity (Fig. 2.8d). The Y198E and R65A 
mutations, which dissociated ∆48 PGAM5 ring oligomers without disrupting the F dimer, impaired 
phosphatase activity, decreasing catalytic efficiency ~2 and ~5 fold, respectively (Fig. 2.8d, Table 
2.2). The negative effect of every mutation disrupting PGAM5 ring assembly on phosphatase 
activity indicated that dodecamer formation is necessary to achieve maximal catalytic efficiency. 
These results also showed that phosphatase activity primarily depends on the interaction between 
the multimerization motif and phosphatase domains through the F dimer interface and that 
organization of F dimers into a hexameric ring through the a3 dimer interface further potentiates 
activity.  
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Fig. 2.8: PGAM5 multimerization is required for catalysis. a. Overview of interactions 
contributing to the stability of the dodecamer assembly in the structure of ∆90 PGAM5 
H105A/MM. b. SEC elution profiles of wild type (WT) and interface-disrupting mutants (R65A, 
H105A, Y198E, F244E, and A4) of ∆48 PGAM5 in 150mM NaCl-containing buffer, highlighting 
the effect of the MM (R65A, A4) and dimer interface (F244E, Y198E) mutants on the 
oligomer/dimer equilibria observed in wild type ∆48 PGAM5. c. EM micrographs of negatively-
stained samples of interface mutants of PGAM5 corresponding to the oligomer peaks for WT and 
H105A, and dimer/monomer peaks for all the other mutants as shown in (b). The insets in top right 
corners illustrate the position of the respective mutations within the PGAM5 dodecamer cartoon. 
Scale bars correspond to 50 nm. d. Phosphatase activity of the WT and mutant variants of ∆48 
PGAM5 measured for 20 nM enzyme and varying concentrations of a phosphorylated ASK1 
substrate peptide. Data are represented as mean +/- S.E.M.. The kinetic parameters Km, kcat and 
kcat/Km were determined using GraphPad Prism and are summarized in Table 2.2. 
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Table 2.2: Phosphatase activity of PGAM5 and its oligomerization-deficient mutants.  
Dephosphorylation of the ASK1 phosphopeptide by WT and mutant variants of ∆48 PGAM5 was 
measured at 20 nM of enzyme concentration and varying concentrations of ASK1 substrate. The 
kinetic parameters Km, kcat and kcat/Km were determined using GraphPad Prism software. Kinetic 
data for PGAM5 variants without measurable phosphatase activity is denoted ND (not 
determined). Data are represented as mean +/- S.E.M.. 
 
Protein Km [µM] Kcat [min-1] Kcat/Km [min-1M-1] 
    
∆48 WT 115.2 ± 5.0 137.20 ± 2.98 1.19 (± 0.06) · 106 
∆48 H105A ND ND ND 
∆48 R288E 174.70 ± 26.99 143.30 ± 12.73 0.82 (± 0.15) · 106 
∆48 F244E ND ND ND 
∆48 A4 ND ND ND 
∆48 R65A 119.9 ± 15.7 23.17 ± 1.55 0.19 (± 0.03) · 106 
∆48 Y198E 86.17 ± 6.19 51.65 ± 1.68 0.60 (± 0.05) · 106 
 
Filament formation does not enhance PGAM5 activity 
 In solutions of physiological ionic strength, ∆48 PGAM5 existed predominantly as 
filaments composed of repeating dodecameric rings (Fig. 2.1c). Although such structures are not 
present in the crystal lattice of ∆54 PGAM534, the unit cell of our ∆90 PGAM5 H105A/MM 
structure reveals rings stacked to form tubular filaments (Fig. 2.9a). Within the filament, each 
successive ring is rotated ~15˚ around the 6-fold symmetry axis relative to the neighboring ring. 
This architecture resembles the filament organization of ∆48 PGAM5 examined by negative-stain 
EM (Fig. 2.9b). In the crystal structure, the lattice interactions that mediate ring stacking lack an 
extensive buried surface area and rely on sparse and non-symmetrically distributed hydrogen bond 
interactions between residues within loops at the perimeter of the rings (Fig. 2.9c and Fig. 2.10a). 
This could explain the apparent lack of structural rigidity in the EM images (Fig. 2.5b). Mutation 
of the hydrogen-bonding residues did not have a measurable effect on formation of the ∆48 
PGAM5 filaments in solution (Fig. 2.10b), suggesting that stabilization of filament formation 
likely occurs through forces independent of loop interactions observed in the crystal structure. 
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Fig. 2.9: Role of PGAM5 filaments in catalysis. a-b. Overview of the (a) crystal packing in the 
∆90 PGAM5 H105A/MM structure (left panel) highlighting a network of stacked rings (right 
panel), which resembles the organization of (b) filaments observed for ∆48 PGAM5 in solution by 
negative-stain EM. c. Overview of the ring stacking interface highlighting the positions of residues 
at the surface of the substrate-binding cleft relative to structural elements contributing to peripheral 
interactions between two adjacent dodecamers within the crystal lattice of the ∆90 PGAM5 
H105A/MM structure. d. Electrostatic surface potential calculated for the ∆90 PGAM5 
H105A/MM dodecamer using APBS71. The positions of the MM outlined in green are shown 
relative to the positions of basic residues R269E and R288E within the positively charged 
substrate-binding cleft as well as the catalytic residue, H105, in the active site. Coloring 
corresponds to the electronegativity of the surface potential as defined in the scale bar, with more 
negatively charged surfaces colored red and positively charged surfaces colored blue. e. Upper 
panel: size exclusion chromatograms of the WT ∆48 PGAM5 purified in buffer containing low 
(150 mM NaCl) or high (750 mM NaCl) salt concentrations compared to the results obtained for 
the R269E and R288E variants. Lower panel: EM micrographs of the negatively-stained samples 
of mutant ∆48 PGAM5 taken from the corresponding primary peak of the purification. f. 
Phosphatase activity of the wild type (WT), catalytically inactive H105A, and the stacking-
impaired R288E variants of ∆48 PGAM5 measured for 20 nM enzyme and varying concentrations 
of a phosphorylated ASK1 substrate peptide. Data are represented as mean +/- S.E.M.. The kinetic 
parameters Km, kcat and kcat/Km were determined using GraphPad Prism and are summarized in 
Table 2.2. Scale bars in (b) and (e) correspond to 50 nm, except for the inset in (b) which 
corresponds to 10 nm. 
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Fig. 2.10: Effect of mutations in the residues making direct contact at the crystallographic 
dodecamer stacking interface. a. Overview of the stacking interface between adjacent rings in 
the crystalline lattice of the ∆90 PGAM5 H105A/MM structure (left panel). Residues forming 
hydrogen bonding interactions at contact sites between rings are highlighted in the right panel. b. 
Elution profiles for ∆48 PGAM5 constructs carrying the indicated mutations of residues identified 
in (a) and purified by size exclusion chromatography (SEC) using a Superose 6 column (GE 
Healthcare) in SEC buffer containing 20 mM Tris-Cl pH 8.0, 500 µM TCEP, and 150 mM NaCl. 
EM micrographs of negatively-stained samples of the PGAM5 mutants taken directly from the 
indicated oligomer peaks observed during SEC are shown to the right.   
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The 2-fold rotational symmetry relating individual monomers within each phosphatase 
dimer results in identical electrostatic surface potentials on both sides of the dodecameric assembly 
(Fig. 2.9d). Basic residues comprise a large positively-charged patch centered on the catalytic 
clefts of each dimer surrounded by somewhat negatively-charged protruding loops. The structural 
and electrostatic symmetry suggests that filament formation lacks directionality and can occur 
from either face of the ring. These characteristics, together with the disruptive effect of high ionic 
strength on PGAM5 filaments (Fig. 2.1d), implicate complementary electrostatic forces in 
stabilizing the formation of PGAM5 filaments in vitro. To test this, we designed two charge-
reversing mutations within the basic cleft, R269E and R288E, and examined their influence on 
PGAM5 filamentation. In buffers with physiological salt concentrations, each mutation reduced 
PGAM5 filament length and formation, with the R288E mutation having the greater effect (Fig. 
2.9e). With the R288E mutant, we then investigated the role filaments play in regulating 
phosphatase activity. The phosphatase activities were similar for both wild type and R288E ∆48 
PGAM5, suggesting that filament formation does not contribute substantially to the catalytic 
efficiency of PGAM5 phosphatase activity (Fig. 2.9f, Table 2.2). 
 
PGAM5 forms large oligomers in cells upon cleavage from IMM 
We investigated whether PGAM5 also organizes into filaments in living cells. Our 
biochemical and structural analysis of the filaments focused on PGAM5 without its membrane-
anchoring helix. This construct approximates the state of PGAM5 generated by PARL or OMA1 
cleavage in response to the loss of mitochondrial membrane potential upon treatment with CCCP, 
a small molecule inhibitor of oxidative phosphorylation. The resulting cleaved PGAM5 is mainly 
detected in mitochondria, with only a fraction detectable in the cytosol6,8,9,11. We explored the 
 42 
subcellular localization and oligomerization of endogenous PGAM5, using CCCP to induce 
cleavage of PGAM5 in HEK293T cells and subcellular fractionation to distinguish between the 
cytoplasmic and mitochondrial pools of PGAM5. In CCCP-treated cells, cleaved PGAM5 
predominantly partitioned to mitochondria (Fig. 2.11a). To assess the oligomeric state of 
mitochondrial PGAM5 before and after cleavage, we used blue native electrophoresis (BN-
PAGE). We confirmed that BN-PAGE could differentiate different sizes of PGAM5 oligomers by 
comparing the migration of recombinant wild type ∆48 PGAM5 and the oligomerization-deficient 
mutant F244E (Fig. 2.11b). By comparing the migration of endogenous PGAM5 in the 
cytoplasmic (cyto) and mitochondrial (mito) fractions of untreated or CCCP-treated cells, we 
observed markedly higher molecular weight species for the cleaved pool of mitochondrial PGAM5 
compared to the uncleaved population, approximating the behavior of the recombinant wild type 
∆48 PGAM5 filaments (Fig. 2.11b). We observed a similar pattern in the cytosolic fraction after 
CCCP treatment, although the cytosolic pool represented only a small fraction of the total PGAM5 
detected.  
To visualize PGAM5 filaments in cells, we focused on cytosolic cleaved PGAM5 due to 
resolution limits preventing the distinction between membrane-tethered and cleaved PGAM5 
molecules in the mitochondrial intermembrane compartment. To increase the pool of the cleaved 
cytosolic PGAM5, we expressed and imaged myc-tagged ∆23 PGAM5 (residues 24-289), 
mimicking the cleaved version, in COS7 cells using confocal microscopy. In a small subset of 
transfected cells, we observed myc-positive wire-like cytosolic structures (Fig. 2.11c). Using two 
higher-resolution imaging techniques, stimulated emission depletion microscopy (STED) and 
structured illumination microscopy (SIM), we visualized PGAM5 filaments throughout the 
cytoplasm in the subset of cells with this PGAM5 phenotype (Fig. 2.11c). 
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Fig. 2.11: Cleaved PGAM5 forms oligomers in cells. a. SDS-PAGE analysis of endogenous 
PGAM5 in HEK293T whole cell lysate (WCL), mitochondrial (mito), and cytoplasmic (cyto) 
fractions 4 hours post CCCP treatment. Uncleaved (UC) and cleaved (C) PGAM5 bands are 
marked by arrows. b. BN-PAGE analysis of endogenous PGAM5 4 hours post CCCP treatment in 
mitochondrial (mito) and cytoplasmic (cyto) fractions. Fractionation samples were normalized 
based on the total protein concentrations determined for the WCL samples. As a reference for 
migration behavior of PGAM5 oligomers, recombinant ∆48 WT (∆48 WT) and the 
oligomerization-deficient mutant ∆48 F244E mutant (∆48 F244E) PGAM5 were run alongside 
cellular fractionation samples on a 4-16% native-PAGE acrylamide gel (Invitrogen). Following 
electrophoresis, gels were immunoblotted with anti-PGAM5 antibody. c. Comparison of myc-
tagged ∆23 PGAM5 (myc-PGAM5) filaments in transiently transfected COS7 cells stained with 
anti-myc antibody using three different imaging methods: confocal microscopy (left panel), 
stimulated emission depletion (STED) microscopy (middle panel), and structured illumination 
microscopy (SIM) (right panel). All scale bars correspond to 5 µm. d. SIM images of myc-tagged 
∆23 PGAM5 filaments in COS7 cells transiently expressing wild type (WT) or the R288E PGAM5 
(red). Nuclei were stained using DAPI (blue). Both scale bars in (d) correspond to 10 µm.  
 
 
As a control, we evaluated the PGAM5 phenotype of the filament disrupting mutant, R288E (Fig. 
2.9e). We did not find any cytosolic filaments in cells expressing the R288E mutant of ∆23 
PGAM5 (Fig. 2.11d). All mutations that disrupted dodecamer assembly and consequently 
formation of PGAM5 filaments in vitro (Fig. 2.8b,c) also eliminated the detection of filaments in 
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cells (Fig. 2.12). Thus, the cellular structures we observed have properties like the PGAM5 
filaments observed in vitro. 
We noted that the architecture of cleaved PGAM5 filaments formed in cells resemble 
cytoskeletal structures. To test for a spatial relationship between PGAM5 filaments and 
cytoskeleton, we assessed PGAM5 filament colocalization with actin fibers or microtubules. 
Although we did not detect overlap between PGAM5 filaments and actin fibers (Fig. 2.13a), 
PGAM5 filaments colocalized with microtubules (Fig. 2.13b). Upon nocodazole treatment to 
disrupt microtubule polymerization, detection of PGAM5 filaments was lost (Fig. 2.14), 
suggesting a potentially intriguing dependence of PGAM5 filament assembly in cells on PGAM5 
association with intact microtubules. 
  
PGAM5 dodecamers promote mitochondrial clustering 
 Under conditions of intact mitochondrial membrane potential, PGAM5 is expected to 
remain in the uncleaved, membrane-tethered form. To examine the importance of PGAM5 
oligomerization in this context, we leveraged the observation that overexpression of full-length 
PGAM5 induced clustering of mitochondria in the perinuclear region5. PGAM5 knockdown has 
an opposite effect on mitochondria, resulting in increased tubular morphology26 and decreased 
stress-induced mitochondrial clustering35. Such effects on mitochondrial behavior stemming from 
changes in PGAM5 abundance may reflect the role of PGAM5 in maintaining mitochondrial 
homeostasis13,26,33. Using confocal imaging of COS7 cells, we evaluated the colocalization of full-
length PGAM5 or PGAM5 mutants and a marker of mitochondrial outer membranes, Tom20 and 
assessed the effect of full-length PGAM5 expression on mitochondrial morphology (Fig. 2.15a). 
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Fig. 2.12: Effect of dimerization interface mutations on PGAM5 filamentation. 
Representative structured illumination microscopy (SIM) images of COS7 cells transiently 
transfected with the myc-tagged ∆23 PGAM5 wild type (WT) and mutant variants. COS7 cells 
were immunostained for Tom20 with anti-Tom20 antibody (green), for PGAM5 with anti-myc 
antibody (red) and for nuclei with DAPI (blue). All scale bars correspond to 10 µm.  
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Fig. 2.13: Colocalization of PGAM5 filaments with cytoskeletal structures. a-b Representative 
confocal images of COS7 cells transiently transfected with the myc-tagged ∆23 PGAM5 construct. 
a. COS7 cells were immunostained for microtubules with anti-b tubulin antibody (green), for 
PGAM5 with anti-myc antibody (red), and with DAPI (blue). b. COS7 cells were immunostained 
for actin with Alexa Fluor-647-phalloidin (red), for PGAM5 with anti-myc antibody (green) and 
for nuclei with DAPI (blue). All scale bars correspond to 10 µm.   
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Fig. 2.14: Effect of nocodazole treatment on PGAM5 filaments. a-b. Representative confocal 
images of COS7 cells transiently transfected with myc-tagged ∆23 PGAM5. a. Untreated COS7 
cells, either untransfected or transfected with myc-tagged ∆23 PGAM5 wild type (WT). Upper 
panel: staining for β-tubulin with anti-β-tubulin antibody (green) and for nuclei with DAPI (blue).  
Lower panel: staining for PGAM5 with anti-myc antibody (red) and for nuclei with DAPI (blue). 
b. COS7 cells transfected with myc-tagged ∆23 PGAM5 wild type (WT) treated with 10 µM 
nocodazole for 45 minutes. Upper panel: staining for β-tubulin with anti-β-tubulin antibody 
(green) and for nuclei with DAPI (blue). Lower panel shows a different set of cells stained for 
PGAM5 with anti-myc antibody (red) and for nuclei with DAPI (blue). All scale bars correspond 
to 15 µm.  
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Consistent with previous reports33, expression of the two catalytically inactive PGAM5 mutants, 
H105A and A4, had opposing effects on mitochondrial clustering. The membrane-tethered H105A 
mutant induced mitochondrial clustering, similar to the effect of overexpressing wild type 
PGAM5; the A4 mutant resulted in fragmentation of the mitochondria (Fig. 2.15a,b).  
The differences in the architecture of recombinant PGAM5 complexes formed by the 
H105A and A4 mutants could explain their effects on mitochondria. Although both mutations 
inactivate PGAM5, the H105A mutant forms higher-order oligomers and the A4 mutant prevents 
multimerization (Fig. 2.8b,c). Thus, we hypothesized that the assembly of the PGAM5 dodecamer, 
and perhaps also filamentation, drives changes in mitochondrial morphology. To test this 
hypothesis, we expressed the F244E mutant, which disrupts the F dimer interface and prevents 
multimerization, and observed that it failed to induce clustering instead causing mitochondrial 
fragmentation similar to the A4 mutants (Fig. 2.15a,b). Expressing of both a3 dimer interface 
mutants (Y198E and R65A), which disrupt ring and filament formation but preserve some 
phosphatase activity, also failed to induce mitochondrial clustering and resulted in a more tubular 
phenotype than the A4 or F244E mutants. These results suggested that mitochondrial-clustering 
phenotype depends on intact dodecamer interfaces of PGAM5, independent from its activity.  
To evaluate if assembly of PGAM5 dodecamers into filaments affects mitochondrial 
clustering, we evaluated the R288E mutation, which disrupted formation of PGAM5 filaments in 
vitro without affecting the structure of the PGAM5 dodecamer (Fig. 2.9e). Expression of the 
R288E mutant induced mitochondrial clustering, suggesting that filament formation is either 
nonessential  
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Fig. 2.15: Multimerization of full-length PGAM5 promotes clustered mitochondrial 
morphology. a. Representative confocal images of COS7 cells transiently transfected with the 
wild type (WT) or mutant full-length myc-tagged PGAM5 constructs and immunostained for the 
OMM marker Tom20 with anti-Tom20 antibody (green), PGAM5 with anti-myc antibody (red), 
and nucleic-stain DAPI (blue). All scale bars correspond to 15 µm. b. Quantification of 
mitochondrial phenotypes observed by confocal microscopy in COS7 cells transiently expressing 
PGAM5 variants as described in (a), based on at least 3 independent experiments per construct. 
Data are represented as mean +/- S.E.M., determined using GraphPad Prism. Untransfected cells: 
n= 122 cells over 3 experimental replicates. Cells expressing PGAM5 WT: n=296 cells over 7 
experimental replicates.  Cells expressing PGAM5 H105A: n= 141 cells over 3 experimental 
replicates. Cells expressing PGAM5 R288E: n= 212 cells over 5 experimental replicates. Cells 
expressing PGAM5 A4: n= 144 cells over 3 experimental replicates. Cells expressing PGAM5 
F244E: n= 186 cells over 4 experimental replicates. Cells expressing PGAM5 Y198E: n= 108 cells 
over 3 experimental replicates. Cells expressing PGAM5 R65A: n=141 cells over 4 experimental 
replicates.     
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for mitochondrial clustering or is precluded when PGAM5 is embedded within mitochondrial 
membranes (Fig. 2.15a,b).  
 
Mitochondrial clustering by PGAM5 is independent of DRP1 
 DRP1, a cytosolic dynamin-family GTPase that binds to its receptors on the OMM to 
promote mitochondrial fission36, is a substrate of PGAM524,33. We investigated if the clustering 
effect of PGAM5 overexpression on mitochondrial morphology depends on DRP1, by assessing 
the mitochondrial morphology in Drp1-/- mouse embryonic fibroblasts (MEFs) upon PGAM5 
overexpression. The smaller size of MEF cells relative to COS7 cells made it difficult to categorize 
the full spectrum of phenotypes noted for COS7 cells (Fig. 2.15a,b), thus we limited the phenotypic 
analysis of MEFs to three categories: (i) tubular/elongated, (ii) fragmented, and (iii) aggregated 
(Fig. 2.17). In untransfected Drp1-/- cells, mitochondrial tubules were more connected and 
elongated37-39 than in wild type MEFs (Fig. 2.16a); however, we were still able to identify all three 
mitochondrial phenotypes (Fig. 2.17). The distribution of phenotypes was comparable to that in 
wild type MEFs, despite differences in the overall appearance of the mitochondrial tubules (Fig. 
2.16b). 
Overexpression of wild-type PGAM5 in wild-type or Drp1-/- MEFs resulted in 
mitochondrial clustering similar to that observed in COS7 cells (Fig. 2.16b,c). Expression of 
F244E PGAM5 in either wild type or DRP1-knockout cells resulted in a shift to the fragmented 
phenotype of mitochondria (Fig. 2.16b,c). Thus, the effects of PGAM5 overexpression on 
mitochondrial phenotypes are independent of DRP1.  
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Fig. 2.16: DRP1 is dispensable for the clustered mitochondrial morphology induced by 
PGAM5. a Representative confocal images of wild type or Drp1-/- MEFs immunostained for the 
OMM marker Tom20 with anti-Tom20 antibody (green) and with DAPI (blue). Scale bars 
correspond to 15 µm. b Quantification of mitochondrial phenotypes observed by confocal 
microscopy in wild type or Drp1-/- MEFs either untransfected or transiently transfected with the 
indicated PGAM5 constructs, based on at least 3 independent experiments per construct. Data are 
represented as mean +/- S.E.M, determined using GraphPad Prism. Untransfected wild type (WT) 
MEFs: n= 123 cells over 3 experimental replicates. WT MEFs expressing full-length WT PGAM5: 
n= 129 cells over 3 experimental replicates. WT MEFs expressing full-length F244E PGAM5: n= 
89 cells over 3 experimental replicates. Untransfected Drp1-/- MEFs: n= 154 cells over 3 
experimental replicates. Drp1-/- MEFs expressing full-length WT PGAM5: n= 1179 cells over 3 
experimental replicates. Drp1-/- MEFs expressing F244E PGAM5: n= 89 cells over 3 experimental 
replicates. c, Representative confocal images of WT or Drp1-/- MEFs transiently transfected with 
the WT or dimer interface mutant (F244E) full-length myc-tagged PGAM5 and immunostained 
for the OMM marker Tom20 with anti-Tom20 antibody (green), for PGAM5 with anti-myc 
antibody (red) and for nuclei with DAPI (blue). All scale bars correspond to 15 µm. 
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Fig. 2.17: Phenotypic categories used for scoring the effect of PGAM5 overexpression on 
mitochondrial morphology in MEF cells. Representative confocal images of mitochondria in: 
untransfected wild type and Drp1-/- MEFs (left panels), wild type and Drp1-/- MEFs transiently 
transfected with full-length wild type PGAM5 (center panels), or wild type and Drp1-/- MEFs 
transiently transfected with full-length F244E PGAM5 (right panels). Cells were immunostained 
for Tom20 with anti-Tom20 antibody (green) and for nuclei with DAPI (blue). All scale bars 
correspond to 15 µm. 
 
PGAM5 localizes at contact sites of clustered mitochondria 
To characterize the spatial distribution of wild-type and F244E PGAM5 at the 
mitochondria, we used STED to visualize the OMM with Tom20 or the IMM with Tim23. In 
untransfected COS7 cells, mitochondria adopted a phenotype in which tubular Tom20-positive or 
Tim23-positive structures extended radially from the perinuclear regions (Fig. 2.18a). In cells 
transiently transfected with wild-type PGAM5, mitochondrial tubules were replaced by circular 
mitochondria clustered in the perinuclear region (Fig. 2.18b). Frequently, single clusters were 
found stacked next to each, appearing as though these membranes were in direct contact (Fig. 
2.18c). PGAM5 was localized exclusively inside of these distorted mitochondrial structures and 
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detected as puncta that mostly colocalized with Tim23 and not with Tom20 (Fig. 2.18b,c). We also 
observed that PGAM5 colocalization with Tom20 only occurred at the sites of contact between 
individual mitochondrial clusters (Fig. 2.18b,c).  
As with confocal analysis (Fig. 2.15a), STED imaging showed that F244E PGAM5 
expression resulted in a fragmented mitochondrial morphology and more diffuse distribution of 
mitochondrial vesicles in the cell (Fig. 2.18b). In contrast to wild type PGAM5, the F244E-positive 
mitochondria did not engage in any apparent inter-mitochondrial contacts and PGAM5 in these 
cells was not colocalized with Tom20. Rather, the F244E mutant was primarily found in Tim23-
positive structures (Fig. 2.18b,c). These data point to a functional importance of PGAM5 
multimerization in bridging adjacent mitochondrial membranes to promote interactions that might 
underlie the clustered phenotype. Our data are also consistent with a localization for PGAM5 at 
the inner mitochondrial membrane and/or possibly also within the intermembrane space, as 
evidenced by partitioning of the PGAM5 signal at the inner periphery of the OMM and 
colocalization with Tim23.  
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Fig. 2.18: PGAM5 localizes at inner mitochondrial membrane and at the membrane contact 
sites. a-d. STED images of COS7 cells that were either a. untransfected or b-c. transiently 
transfected with wild type (WT) or F244E full-length myc-tagged PGAM5. Tom20 was visualized 
with anti-Tom20 antibody (green), Tim23 with anti-Tim23 antibody (green) and PGAM5 with 
anti-myc antibody (red). White arrows indicate contact sites between mitochondrial membranes in 
which myc-tagged PGAM5 was found colocalized with Tom20. Scale bars correspond to 5 µm in 
(a), 5 µm in (b) and 1 µm in (c). d. Upper panels show representative close-up views of PGAM5 
localization to the sites of mitochondrial membrane contacts. White arrows indicate sites of 
PGAM5 (myc, red) overlap with the outer mitochondria membrane marker Tom20 (green).  
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2.4 DISCUSSION 
Here we investigated activation mechanisms of the PGAM5 phosphatase, whose 
remarkable spectrum of functions in mitochondria parallels the pleiotropic roles of the organelle 
itself. We discovered that PGAM5 assembles into symmetric rings in solution that polymerize into 
filaments. We showed that the ring structure, first observed by Chaikuad and colleagues for a 
PGAM5 construct containing its linker and phosphatase domains34, also forms when phosphatase 
domain without these additional contiguous regions is crystallized in the presence of a peptide 
corresponding to the multimerization motif. Observation of PGAM5 rings in solution indicates 
that this form is an energetically favored state of the PGAM5 phosphatase.  
Our studies demonstrate that the assembly into the dodecameric ring is an essential 
determinant of efficient catalytic activation of PGAM5. The multimerization step is critical: the 
interaction between a multimerization motif within the linker domain and a pair of phosphatase 
domains is essential for stabilization of the phosphatase in the active state. This interaction is 
further stabilized by neighboring subunits in the oligomer. The linker domain of PGAM5 mediates 
several protein-protein interactions, such as binding of KEAP1 and XIAP ubiquitin ligases5,9 and 
Bcl-XL12. Through such interactions, the linker domain may regulate oligomerization, further 
tuned by possible post-translational modifications within the linker region. The sufficiency of the 
presentation of the multimerization motif in trans could create a mechanism for propagation of 
regulatory modifications from one PGAM5 monomer to another, or even between dodecamers, if 
PGAM5 subunits in the oligomers are capable of exchanging. This could equip PGAM5 with the 
ability to store information, such as the status of phosphatase domain activation, in a manner 
analogous to that described for CamKII40.  
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The multimeric organization of PGAM5 might also have important implications for its 
substrate specificity as a phosphatase. Some PGAM5 substrates form higher-order oligomeric 
structures, including DRP1, which self-assembles into rings or filaments36,41. GTP hydrolysis, an 
important step in mitochondrial constriction by DRP1, is thought to release DRP1 from its 
mitochondrial receptors and triggers DRP1 filaments to curl into ring-shaped oligomers, often 
dodecamers41, analogous to the PGAM5 oligomers that we describe here. Although DRP1 
associates with the OMM and PGAM5 resides primarily in IMM, we observed that PGAM5 
colocalizes with the OMM marker at contact sites between two adjacent mitochondrial vesicles 
within the mitochondrial clusters promoted by PGAM5 overexpression. These PGAM5-enriched 
contact sites may represent a type of membrane fusion or fission intermediate involving the 
formation of local membrane pores 42-47, which could facilitate interactions between DRP1 and 
PGAM5.  
Mitochondrial morphology and function are tightly linked. The IMM is intricately 
structured and contains functionally distinct regions, such as inner boundary regions that are close 
to OMM, cristae invaginations and cristae junctions48-51. Formation of inner membrane 
supercomplexes by IMM proteins, such as adenine nucleotide translocator52, ATP synthase50,53 
and multiprotein Mitofilin complex (MitOS)54, is important for structural organization of the 
functional domains within the IMM. Our data demonstrate that PGAM5 resides primarily in the 
IMM and acts independently of DRP1 to influence mitochondrial morphology, suggesting that 
PGAM5 has an intrinsic ability to alter mitochondrial architecture. Furthermore, oligomerization, 
but not activity, appeared crucial for this ability of PGAM5. Hence, PGAM5 oligomerization 
within IMM may play a structural role in the maintenance of the functional mitochondrial 
membrane architecture.  
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Our finding that cleaved PGAM5 forms filaments composed of dodecameric phosphatase 
rings both in vitro and in cells adds a new dimension of complexity to PGAM5 signaling. Filaments 
did not influence the catalytic rate of PGAM5 in vitro nor the ability of full-length PGAM5 to 
influence mitochondrial morphology in cells. However, cleaved PGAM5, which accumulates with 
time in the cytosol, sensitizes cells to apoptosis through sequestration of the negative regulator of 
apoptosis, the ubiquitin ligase XIAP9. Other cytosolic effectors of death pathways form 
filamentous structures that are essential for executing cell death programs, including the caspase-
8 associated death complex55, the caspase-1 containing inflammasomes47 and the RIP1/RIP3 
necrosomes56. PGAM5 filamentation could ensure highly processive or cooperative 
dephosphorylation in these processes. We found that cytosolic PGAM5 filaments colocalized with 
microtubules and only formed when microtubules are intact. This phenomenon may relate to the 
link between PGAM5 and the stability of the Miro2 GTPase, which involves KEAP1 and the 
formation of a ternary complex with the Nrf2 transcription factor, to control stress-induced 
retrograde trafficking of mitochondria35. It is also possible that PGAM5 filaments formed upon 
PGAM5 cleavage reside primarily inside the mitochondria, playing yet unknown role(s). 
 Although we still know little about the regulation of PGAM5 activity, the enhanced 
phosphatase activity in oligomerization-competent PGAM5 supports the need for tight regulation 
of this intramolecular interaction. How binding partners or posttranslational modifications regulate 
PGAM5 catalytic activity and/or oligomerization is a topic of future studies. An exciting 
possibility is the pharmacological regulation of PGAM5 signaling through regulation of the 
interaction between the multimerization motif and the phosphatase domain. Compounds 
mimicking this binding event could be of potential therapeutic interest in the treatment of stroke, 
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myocardial infarction, and other diseases by stimulating the mitophagy-promoting functions of 
PGAM532.  
 
2.5 METHODS 
Protein expression and purification: Wild type full-length PGAM5 cDNA (corresponding to the 
PGAM5 long isoform (PGAM5L), residues 1-289) was purchased from Addgene. For bacterial 
expression and purification, the ∆90 PGAM5 (residues 91-289) and D48 PGAM5 (residues 49-
289) were cloned into the pET28a expression vector (Novagen). These constructs were N-
terminally tagged with hexahistidine (6X-HIS) followed by a linker sequence encoding a TEV 
protease cleavage site (ENLYFQS). Full-length and ∆23 (residues 24-289) PGAM5 variants for 
mammalian cell expression and imaging were cloned into the pcDNA3.1+ vector (Invitrogen). 
These constructs contained an internal myc-tag (EQKLISEEDL) inserted between residue 42 and 
43 of the PGAM5 sequence. Mutations were introduced using either QuickChange mutagenesis or 
through Gibson assembly57. Primers used for mutagenesis are as follows: H105A (Forward: 5’-
acatcttcctcatcagggcttcccagtaccacgtgg-3’ Reverse: 5’-ccacgtggtactgggaagccctgatgaggaagatgt-3’), 
Y198E (F: 5’-gctccgtcttcctcatactgcacagcttccggc-3’ R: 5’-gccggaagctgtgcagtatgaggaagacggagc-
3’), R65A (F: 5’-agagacagtggttctgccctgtcccagttggg-3’ R: 5’-cccaactgggacagggcagaaccactgtctct-
3’), F244E (F: 5’-gccagccttcaggaggctcctgcagtgctctgcac-3’ R: 5’-
gtgcagagcactgcaggagcctcctgaaggctggc-3’), R288E (F: 5’-
cctcccgacaagatcactgaatcctgagatccgaattc-3’ R: 5’-gaattcggatctcaggattcagtgatcttgtcgggagg-3’). 
Mutation of WT A4 was done by sequential mutation of W58A and D59A and followed by W62A 
and D63A. W58A/D59A (F: 5’- gtcccagttgggggccgcgacaccggggccc-3’ R: 5’- 
gggccccggtgtcgcggcccccaactgggac-3’), W62A/D63A (F: 5’- gtggttctcgcctggccgcgttggggtcccaga-
3’ R: 5’- tctgggaccccaacgcggccaggcgagaaccac-3’).  
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Y92A (F: 5’-cgtggccttggctttggcgtggtccagcttggac-3’ R: 5’-gtccaagctggaccacgccaaagccaaggccacg-
3’), D111A (F: 5’-cccagtaccacgtggccggctccctggagaag-3’ R: 5’-
cttctccagggagccggccacgtggtactggg-3’), K191A (F: 5’-tgcacagcttccggcgcccaatgagacacggg-3’ R: 
5’-cccgtgtctcattgggcgccggaagctgtgca-3’), R218A/E220A (F: 5’-gtaactgtcctccgcctgcgcggc-
0=atctgcgcgg-3’ R: 5’-ccgcgcagatgccgcgcaggcggaggacagttac-3’). 
For recombinant protein expression, BL21 DE3 pLysS E. coli cells transformed with 
pET28a-PGAM5 constructs were cultured in Luria Broth media supplemented with kanamycin 
(30 µg/mL) at 37o C until 0.4 optical density at 600 nm was reached. Protein expression was 
induced with 0.2 mM IPTG and cells were cultured for additional 12 hours at 25o C. Following 
collection by centrifugation at 5000 x g, cell pellets were resuspended in Lysis Buffer (20 mM 
Tris-Cl pH 8.0, 500 mM NaCl, 0.5 mM TCEP, 5% glycerol, 20 mM Imidazole pH 8.0 
supplemented with EDTA-free protease inhibitors (Roche)). Cells were lysed by sonication at 25% 
of max power in cycles of 4s on and 2s off for 5 minutes. Lysates were clarified by centrifugation 
at 18,000 x g and loaded by gravity flow on HiTrap Ni-NTA resin (GE Healthcare). Protein was 
eluted using Elution Buffer (20 mM Tris-Cl pH 8.0, 500 mM NaCl, 0.5 mM TCEP, 5% glycerol, 
200 mM Imidazole pH 8.0) and exchanged into buffer containing 20 mM Tris-Cl pH 8.0, 150 mM 
NaCl, and 0.5 mM TCEP using a 10 kDa cutoff concentrator (Millipore). The sample was further 
purified by size exclusion chromatography (SEC) using a Superose 6 10/300 GL Increase column 
(GE Healthcare) equilibrated in buffer containing 20 mM Tris-Cl pH 8.0, 150 mM NaCl and 0.5 
mM TCEP. Salt titration experiments were performed by SEC in buffer conditions containing 20 
mM Tris-Cl pH 8.0, 0.5 mM TCEP and concentrations of NaCl ranging from 150 mM to 1 M.  
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Peptides: The ASK1 phosphopeptide (NFEDH(pS)APPSP) and the PGAM5 multimerization 
motif (MM) peptide (GPGVWDPNWDRREP)33, were purchased at a purity of 95% or greater 
(Elim Biopharma). Peptides were resuspended in 20 mM Tris-Cl pH 7.5, aliquoted, and flash 
frozen in liquid nitrogen prior to storage at -80o C.  
 
Negative-stain sample preparation and data acquisition: Homemade grids were prepared for 
negative-stain experiments by depositing a thin plastic layer on the surface of 400-mesh copper 
grids (Ted Pella) floated on 2% amyl acetate (EMS)58. Air-dried grids were then coated with ~3 
nm of continuous carbon film, negative glow discharged, and loaded with 2.5 uL of purified 
PGAM5 (~0.01-0.1 mg/mL). Following a 30s incubation, grids were briefly dipped in 2 drops of 
sample buffer and one drop of 0.75% uranyl formate staining solution with blotting performed 
between drops by touching the edge of the grid briefly to the surface of Whatman 1 filter paper. 
Sample grids were dipped in a second drop of stain for 30 seconds, blotted on filter paper, and air 
dried prior to imaging. Images were collected using a 120 kV Tecnai T12 (FEI) microscope 
equipped with a Gatan 4K x 4K CCD camera at 52K magnification corresponding to a pixel size 
of 2.21Å.  
 
Cryo-EM sample preparation, data acquisition and processing: For cryo-EM experiments, we 
first screened grid type and protein buffer to identify optimal conditions for data collection. We 
observed significant orientation bias as well as aggregation on traditional Quantifoil 1.2/1.3 400 
mesh spacing gold grids (Electron Microscopy Sciences) that could not be improved by changes 
in buffer conditions (i.e. varying salt concentration, addition of glycerol, addition of low 
concentrations of detergent). While aggregation was somewhat alleviated by sample application 
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on C-flat 1.2/1.3 holey thick carbon grids (Electron Microscopy Sciences), sample quality 
appeared to be the best for 3 µL of purified PGAM5 sample (at 0.10 mg/mL) in ring stabilization 
buffer (20 mM Tris-Cl pH 8.0, 600 mM NaCl, 0.5 mM TCEP) applied to freshly glow-discharged 
Lacey Formvar/Carbon 400 mesh continuous carbon coated copper grids (Ted Pella) placed inside 
a Vitrobot Mark IV (FEI) equilibrated to 4° C and 100% humidity. Following a 10 second 
incubation, grids were blotted between Whatman 1 paper for 6 seconds, and plunge-frozen in 
liquid ethane. Images were recorded using a 300kV Titan Krios microscope (FEI) equipped with 
a K2 Summit detector (Gatan) operated in super-resolution mode (UC Berkeley). 6543 images 
were collected at a nominal magnification of 22.5K, corresponding to a pixel size of 0.53 Å. Dose-
fractionated movies were acquired at an electron flux of 1.8 e-1/A2 over 7.75 seconds with 0.25 
second exposures per frame (31 frames total), corresponding to a total dose of 55 e-1/Å2. Images 
were recorded with a defocus range of -1 to 2.5 μm. 
 Frame-based motion correction, 2X binning, and dose weighting were performed on dose-
fractionated image stacks using MotionCor259 resulting in one integrated image per stack with a 
pixel size of 1.07 Å. The contrast transfer function was estimated from motion corrected, non-
dose-weighted images using GCTF version 1.0660. From an initial subset of micrographs, 
approximately 1000 particles were manually picked and subject to likelihood-based 2D 
classification in Relion 2.061 to generate templates for automated particle selection using 
Gautomatch version 0.5560. In total, 131,396 particles were extracted at a box size of 190 pixels 
with 2.14 Å/pixel and subject to 2D-classification to eliminate particles of poor quality resulting 
in a dataset of 22,422 particles corresponding to orientations in which C6 symmetry of the 
dodecameric assembly of ∆48 PGAM5 was observed. The final selected particles were re-centered 
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and re-extracted at full pixel size to generate the class average shown in Fig. 2.3a. Data collection 
details are reported in Supplementary Table 2.1. 
 
Supplementary Table 2.1 Cryo-EM data collection, refinement and validation statistics 
 ∆48 PGAM5 
Data collection and 
processing 
 
Magnification    22,500 
Voltage (kV) 300 
Electron exposure (e–/Å2) 1.8 
Defocus range (μm) -1.0 – 2.5 
Pixel size (Å) 0.53 
Initial particle images (no.) 131,396 
Final particle images (no.) 22,422 
 
 
X-ray crystallography: The ∆90 H105A PGAM5 construct was crystallized using hanging drop 
vapor diffusion at room temperature in the presence of the ASK1 phosphopeptide alone or together 
with the MM peptide. The electron density corresponding to the ASK1 peptide could not be 
resolved in any of the structures. For crystallization of ∆90 H105A PGAM5 with the ASK1 
peptide, protein was concentrated to 5 mg/mL and incubated with the peptide on ice at a 5:1 molar 
ratio of peptide:protein. Crystals were grown in a 2 µL drop (1 µL protein + 1 µL reservoir 
solution) against a reservoir solution comprised of 100 mM HEPES pH 7.5, 200 mM MgCl2 and 
30% w/v PEG 400. For crystallization of the ∆90 H105A PGAM5 in complex with the MM 
peptide, protein at a concentration of 7.5 mg/mL was incubated on ice with 3:3:1 molar ratio of 
ASK1 peptide:multimerization motif peptide:protein. Crystals were grown in 2 µL drops (1 µL 
protein + 1 µL reservoir solution) equilibrated against reservoir solution containing 100 mM Tris-
Cl pH 7.0, 200 mM MgCl2 and 10% w/v PEG 8000. Crystals from both conditions were 
cryoprotected with Paratone-N oil and flash-cooled to 100 K in liquid nitrogen.  
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X-ray diffraction data were collected at 1.111 Å, 77K at the ALS 8.3.1. beamline 
(Berkeley, CA) on a Pilatus 6M detector. Data were indexed with XDS62, scaled in Aimless63 and 
phases determined in Phaser64. ∆90 PGAM5 H105A crystals diffracted to 1.7 Å in space group 
P212121 and with unit cell dimensions: a = 71.0 Å, b = 72.0 Å, c = 81.9 Å, a = b = g = 90° and 
with two molecules in the asymmetric unit. A solution was generated by molecular replacement 
using one copy of PDB 3MXO as the search model. Crystals of ∆90 PGAM5 H105A/MM 
diffracted to 2.6 Å in the space group P212121 with unit cell dimensions: a = 49.3 Å, b = 242.5 Å, 
c = 272.5 Å, a = b = g = 90° and with twelve molecules in the asymmetric unit. The structure was 
solved by molecular replacement using a single monomer of PDB 5MUF and searching for 12 
copies in the asymmetric unit. Refinement was performed in Phenix65 with iterative rounds of 
model building in Coot66. Model quality was assessed with MolProbity67 and coordinates deposited 
in the RCSB PDB databank under the PDB codes 6CNI [http://dx.doi.org/10.2210/pdb6CNI/pdb] 
(∆90 PGAM5 H105A) and 6CNL [http://dx.doi.org/10.2210/pdb6CNI/pdb] (∆90 PGAM5 
H105A/MM). Detailed statistics for data collection and structure refinement reported in Table 1. 
 
Phosphatase activity assay: Phosphatase assays were performed at room temperature for wild 
type and mutant constructs of 6xHIS-∆48 PGAM5 (A4, R65A, H105A, Y198E, F244E, R269E, 
and R288E). ASK1 phosphopeptide was serially diluted (0 – 200 µM) into reaction buffer (20 mM 
Tris-Cl pH 8.0, 150 mM NaCl and 0.5 mM TCEP) and the assay was started by the addition of 
PGAM5 (20 nM). The reaction was quenched at various time points with the addition of malachite 
green (Promega) and the total free phosphate in solution measured as the absorbance at 620 nm. 
Initial rates and Michaelis-Menten kinetic parameters were calculated in Prism (GraphPad) and 
are reported in Table 2. 
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Subcellular fractionation: HEK293T cells (ATCC) cultured under normal conditions were 
treated with CCCP (50 µM) (Carbonyl cyanide 3-chlorophenylhydrazone, Sigma Aldrich) 
prepared in complete media for 4 hours prior to harvest. Following treatment, subcellular 
fractionation of cellular cytoplasm and mitochondria was performed by resuspending harvested 
cells first with plasma membrane (PM) permeabilization buffer (20 mM HEPES, 100 mM Sucrose, 
2.5 mM MgCl2, 100 mM KCl, 10 mM DTT, 0.025% digitonin, pH 7.4) supplemented with DNase 
(Roche) and complete protease inhibitors without EDTA (Roche). Following incubation at 4o C 
for 30 minutes with end over end mixing, membrane fractions were separated from cytosol by 
centrifugation at 4o C and 13,000 x g for 10 minutes. Supernatant was collected as the cytosolic 
(cyto) fraction. The remaining pellet was washed twice by resuspending in cold PBS and 
centrifugation at 4o C and 600 x g for 5 minutes in between washes. Resuspended mitochondrial 
membranes were then solubilized in a volume of mitochondrial permeabilization buffer (20 mM 
BisTris, 50 mM NaCl, 10% glycerol, 10 mM DTT, 2% digitonin, pH 7.4, supplemented with 
protease inhibitors) equivalent to the volume of PM buffer used and incubated with end over end 
mixing for 30 min at 4o C prior to one final centrifugation at 4o C and 13,000 x g for 10 minutes. 
Supernatant from this fraction was collected as the mitochondrial (mito) fraction. Samples were 
prepared for SDS-PAGE loading controls and blue native-PAGE (BN-PAGE) by adding 
equivalent volumes of either standard SDS-PAGE loading dye or 10X BN-PAGE loading dye (100 
mM Bis-Tris pH 7.0, 500 mM 6-amino-nexamoic acid, and 5% Coomassie Blue R-250), 
respectively. Samples for SDS-PAGE were normalized for concentration and subject to 
immunoblotting with antibodies against PGAM5 (1:3000) (kind gift from Z. Wang), b-tubulin 
(1:2000) (Cell Signaling Technologies, Inc., 2128S), and Tom20 (1:100) (Santa Cruz 
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Biotechnologies, Inc., sc-17764). Uncropped scans of blots shown in Fig. 2.11a are included in the 
supplementary information (Supplementary Figure 6). 
 
Blue Native-PAGE: BN-PAGE was performed for equivalent volumes of the total fractionation 
sample supplemented with BN-PAGE loading dye68,69. Samples were loaded onto a 4-16% Native-
PAGE gel (Invitrogen) and electrophoresed under 8 mA of constant current in blue cathode buffer 
(Invitrogen) until the dye front had migrated approximately one-third of the way through the 
resolving gel. Next, the blue cathode buffer was replaced with clear anode buffer (Invitrogen) and 
electrophoresis continued at 150V for 60 minutes, then increased to 250V for the remainder of the 
experiment (45 minutes). Prior to transfer to PVDF (Millipore) and immunoblotting, the native 
gels was soaked for 10 minutes in Tris-glycine transfer buffer supplemented with 20% methanol 
and 0.05% SDS. Following the transfer, the PVDF membrane was completely destained in 100% 
methanol, then equilibrated in blocking buffer (5% w/v milk prepared in TBST buffer) prior to 
immunoblotting with anti-PGAM5 antibody. 
 
Confocal imaging: Monkey kidney COS7 cells (obtained from J. Kuriyan, UC Berkeley) were 
cultured at 37o C in 5% CO2 with DMEM supplemented with 10% FBS, and 1% Penicillin-
Streptomycin (Thermo Fisher). Mouse embryonic fibroblasts (obtained from D. Chan, Caltech) 
were cultured at 37o C in 5% CO2 with DMEM supplemented with 10% FBS, 100 μM Non-
Essential Amino Acids and 1% Penicillin-Streptomycin (Thermo Fisher). For imaging, COS7 and 
MEF cells were plated at a density of 0.9 x 105 cells per well in a 6 well plate (Corning) on acid-
washed glass coverslips and grown for 16 hours at 37oC. Cells were then transfected with 500 ng 
of full-length or cleaved (D23) PGAM5 using Lipofectamine 3000 (Invitrogen) and incubated for 
 66 
24 hours at 37o C. For nocodazole treatments, relevant cells were incubated with 10 μM nocodazole 
in media for 45 minutes at 37o C. Following transfection and drug treatment, cells were washed 
with cold PBS, and fixed with 3.7% formaldehyde for 1 hour at room temperature. After three 
rinses with PBS, cells were permeabilized with 0.1% Triton X-100 for 5 minutes, then washed 
three times with PBS. Permeabilized cells were incubated with the blocking buffer (1% BSA in 
PBS) for 5 minutes at room temperature, then for 1 hour at 37o C with blocking buffer 
supplemented with primary antibodies. Those included anti-myc (mouse, 1:6000 dilution in 
blocking buffer) (Millipore, 05-724), anti-Tom20 (rabbit, 1:250) (Santa Cruz Biotechnology, SC-
17764), anti-b-tubulin (rabbit, 1:25) (Cell Signaling Technologies, 2128S), anti-b-tubulin (rabbit, 
1:250) (Abcam, Ab179513) or Alexa Fluor-647 Phalloidin (1:20) (Thermo Fischer, A22287). For 
Tim23 labeling, blocking buffer contained 10% FBS and primary labeling used Anti-Tim23 
antibody (rabbit, 1:250) (Proteintech, 11123-1-AP). Coverslips were washed three times with PBS 
and incubated with respective secondary antibodies: FITC-488 (rabbit, 1:500) (Invitrogen, A-
11034) and Alexa-647 (mouse, 1:500) (Invitrogen, A327728) for 1 hour at 37o C in the dark. 
Following three washes with PBS, samples were incubated with the nuclei stain DAPI (1:1000 
dilution in water) (Thermo Fischer, D1306) for 5 minutes at room temperature. Following three 
final water washes to remove excess DAPI, coverslips were mounted using ProLong Gold 
(Invitrogen) and dried overnight at room temperature in the dark. Imaging was done using a Nikon 
TIRF microscope with a Yokagawa CSU-X1 spinning disk confocal consisting of 405, 491, 561 
and 640 nm lasers with the use of a 60x objective. Data were processed using FIJI v1.0 (55).  
 
Structure illumination imaging (SIM): COS7 cells for SIM imaging were cultured, transfected, 
and prepared for imaging as for confocal microscopy. Slides were imaged on an N-SIM (OMX 
 67 
microscope with 405nm, 488nm, 561nm and 640nm lasers) using an Apo TIRF 100x objective 
with 1.56 oil in 3D mode and standard operating procedure. Image reconstruction was performed 
in SoftWoRx v6.5.2 (GE Healthcare). 
 
Stimulated Emission Depletion (STED) imaging: COS7 cells for STED imaging were cultured, 
transfected, and prepared for imaging as for confocal and SIM microscopy, however using 
different secondary antibodies: secondary Alexa-594 (rabbit, 1:500) (Invitrogen, R37117) and 
Alexa-647 (mouse, 1:500) (Invitrogen) antibodies. Images were acquired using a Leica Stimulated 
Emission Depletion (STED) SP8 microscope (equipped with a white light laser, a 775 nm 
depletion laser and 100x objective HC PL APO 100x/1.40 OIL) using standard operating 
procedure. Images were processed in FIJI v1.070.  
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Chapter 3: 
Identification and characterization of novel PGAM5 modulators 
 
This work was done in collaboration with Trent Balius, PhD from Brian Shoichet’s lab at UCSF. 
Contributions are as follows: Karen Ruiz, Trent Balius and Natalia Jura developed the project. 
Karen Ruiz expressed, optimized and purified each of the protein constructs, performed cell-based 
flow cytometry experiments, compound testing, activity assays, X-ray crystallography acquisition, 
processing and data analysis. Trent Balius designed and refined the compounds and provided 
experimental feedback. Christopher Agnew helped with X-ray crystallography data acquisition 
and processing and performed control BMPR2 kinase assay. Natalia Jura contributed to the project 
development and data analysis.   
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3.1 Introduction 
Phosphoglycerate mutase 5 has continued to develop as an interesting subject of study for 
its wide variety of cellular roles, its unique mechanism of activation, and its cellular migration. 
Despite the strides in our collective understanding of PGAM5, many questions still surround this 
atypical protein phosphatase. PGAM5 has been well established as a participator in various cell 
stress and death pathways1-6 and has been implicated as a key regulator of mitochondrial dynamics 
through its activity as a protein phosphatase and as a protein binding partner7,8, yet all of these 
identified connections lack information on and cellular context of PGAM5’s oligomeric status and 
leave us without a way to effectively modulate this phosphatase’s higher order structure formation. 
PGAM5’s cellular localization has been pinpointed to the mitochondria, and its cleavage from the 
membrane and release into the cytosol has been established, however, whether PGAM5 natively 
exists as a single monomer, a constitutive dimer,  a dodecamer or higher order structure when 
docked to the mitochondria has not yet been studied. Similarly, PGAM5’s catalytic activity, if any, 
while in a membrane-tethered state has yet to be elucidated. These same questions remain open 
with regard to PGAM5’s wide range of binding partners and protein substrates both inside the 
mitochondria and in the cytosol; despite the identifications of these interactions, the oligomeric 
state of PGAM5 remains a mystery. It remains a possibility that PGAM5’s interactions with its 
wide variety of protein binding partners and its ability to function as a signaling node between 
mitochondrial homeostasis and cell death could be regulated by its various multimeric states.  
Our findings have verified earlier reports that PGAM5’s phosphatase activity is dependent 
on its ability to form higher order structures and this activity is directly linked to its ability to 
oligomerize9.The exact physiological role this oligomerization plays in the cell is still unknown 
and would require spatial and temporal separation of PGAM5’s various oligomeric states. 
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PGAM5’s multiple cellular functions, combined with its ability to self-regulate its phosphatase 
activity through higher order structure formation, however, make it technically challenging to 
parse PGAM5’s multiple functions and understand the various ways in which PGAM5 regulates 
the mitochondria and contributes to cell death. Our observation that PGAM5’s ability to remodel 
the mitochondrial membrane is independent from its interactions with Drp1 lead us to wonder how 
PGAM5 is able to remodel the mitochondrial membrane seemingly only through its ability to form 
higher order structures and add another layer of complexity to understanding PGAM5’s role in the 
mitochondria. Now that we understand PGAM5 is able to self-associate into dimers, observe 
dimers are able to adjacently interact to form dodecamers, these dodecamers have the ability to 
polymerize, one of the most pressing questions in the PGAM5 and mitochondrial field is how 
PGAM5’s multiple states are regulated in its different cellular contexts, considering PGAM5’s 
higher order structure formation is directly tied to its phosphatase activity, and given its migratory 
abilities. To address these questions, our lab has begun a collaboration with the Shoichet lab at 
UCSF to develop and test novel regulators of PGAM5’s oligomeric states.  
 
3.2 RESULTS 
Effect of PGAM5 on cell death 
An interesting phenomenon observed visually during our confocal imagining experiments 
with cells expressing wild type Δ23 PGAM5 was that transfected slides showed a higher than 
average amount of cell death following transfection. This observation across different experiments 
led us to question whether expression of this construct could in some way contribute to cell death. 
In order to explore the role cleaved PGAM5 has on the cell when it is no longer localized to the 
mitochondria, we generated and expressed a ‘cleaved’ construct of PGAM5 lacking the 
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transmembrane domain and compared the effect on cell viability against a full-length construct. 
To this end, both full-length and cleaved Δ23 PGAM5 were cloned into a GST-containing pIRES2 
vector10, allowing for further study of the downstream effects of PGAM5 cleavage and release 
from the mitochondria.  
In order to quantify and compare the effects of PGAM5 cleavage on cell health, we 
expressed the truncated Δ23 construct of PGAM5 in immortalized suspension human T 
lymphocyte Jurkat cells. As a control, we also expressed full length PGAM5 containing an intact 
mitochondrial targeting sequence in parallel. 24 hours post-transfection, flow cytometry was used 
to separate transfected cells expressing PGAM5 and GPF from untransfected cells. The presence 
of phosphatidylserine on the outer leaflet of the plasma membrane was used to detect and quantify 
the cells undergoing apoptosis through the use of Annexin V stain. Use of GFP and Annexin V 
allowed for us to calculate the amount of transfected cells in each experiment through the presence 
of GPF and further subgroup them into living cells with little to no expression of 
phosphatidylserine or dying cells presenting phosphatidylserine on the outer leaflet of the cell, as 
indicated by high Annexin V signal. Expression of full-length mitochondrially tethered PGAM5 
results in an average of 25% cell death, while expression of our Δ23 construct lacking the 
transmembrane domain resulted in an average of 60% cell death as indicated by the total percent 
dead Jurkat cells (Fig. 3.1). In order to test whether this increase in cell death was due to PGAM5’s 
phosphatase activity, we introduced the catalytic mutation H105A into both the full length and 
truncated Δ23 constructs and observed no difference in the amount cell death, suggesting the 
ability of PGAM5 to mediate cell death is dependent on its catalytic ability. Interested in whether 
this observed increase in cell death is caused by PGAM5’s ability to dodecamerize or form 
filaments, we introduced our dimerization, dodecamerization and filamentation mutations into the 
 80 
full length and Δ23 cleaved construct, expressed and compared the resulting amount of cell death. 
Similar to expression of catalytically dead truncated PGAM5, expression of Δ23 cleaved dimer 
mutant F244E or Δ23 cleaved WT A4 results in no increase in cell death, further validating the 
requirement of PGAM5’s phosphatase activity as a key role in its ability to result in cell death. In 
an effort to parse whether this was directly tied to PGAM5’s ability to form dodecamers or ability 
to filament, we expressed R288E in full length and cleaved form, and observed that expression of 
the cleaved form of R288E does not result in a higher incidence of cell death, suggesting that 
filamentation is somehow correlated with cell death. Interestingly, we observed that expression of 
Y198E, the mutant able to ablate dodecamer formation through disruption of the α3 helix 
interaction results in a higher incidence of cell death in the cleaved form. While puzzling, this 
result suggests PGAM5-mediated cellular death is dependent on filament formation.  
While interesting, our findings bring up further questions surrounding the role of PGAM5 
oligomerization in the cell. Our observations that PGAM5’s ability to form a higher order oligomer 
is be tied to its ability to cause cell death make it essential to have tools to finely regulate its 
phosphatase activity and higher order oligomerization. We are currently only able to regulate 
PGAM5’s higher order structure formation with point mutations and would require chemical tools 
in the form of small molecules to probe PGAM5 formation of filaments and higher order structures 
in detail.  To this end, we began a collaboration with a computational biology lab to identify such 
molecules.  
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Figure 3.1: Quantification of Jurkat cell death in the presence PGAM5 expression. 
Percentage of transfected cells that have been identified as dead expressing full length PGAM5 
expressing cells indicated in striped bars, while cleaved Δ23 PGAM5 expressing cells indicated in 
colored bars.  
 
Compound identification and testing 
As with the majority of other phosphatases, there are no known drug modulators of 
PGAM5 commercially available, a technological hurdle that makes studying PGAM5 more 
challenging but one which we sought to address with our newfound structural insights. In our 
earlier work, we have shown that activation of PGAM5’s phosphatase activity is dependent on the 
specific interaction between the phosphatase domain and the adjacent multimerization motif 
localized in the linker region of the protein. By analyzing our crystal structure of PGAM5, we 
were able to observe the interaction of the multimerization motif with its catalytic core induces the 
formation of a small allosteric pocket in the phosphatase domain and presents a potential site for 
drug modulation. Formation of this pocket introduces a novel way to regulate PGAM5’s activity 
through the identification and optimization of chemical compounds to activate or inhibit PGAM5’s 
phosphatase activity. This more detailed understanding of the molecular mechanism through 
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which PGAM5’s activity is regulated, and PGAM5’s role in a myriad of mitochondrial and cellular 
roles, make it a compelling drug target and a region of interest for our studies. 
PGAM5’s catalytic activation requires the specific interaction between the catalytic core, 
the PGAM domain, with the adjacent multimerization motif (MM) tucked inside the linker domain. 
This interaction is unique and presents the perfect modulation site, as the multimerization motif 
sequence is a conserved unique feature of PGAM5 not found in the rest of the phosphoglycerate 
mutase family, even in the Sts phosphatases which have been found to similarly dimerize and 
which possess tyrosine phosphatase activity11.  
In an effort to generate a chemical toolkit with which to regulate PGAM5 activity, we 
formed a collaboration with the lab of Dr. Brian Shoichet at UCSF and worked in collaboration 
with Trent Balius to identify and test compounds to inhibit PGAM5’s higher order structure 
formation and phosphatase activity. To this end, we employed the use of the in silico screening 
platform DOCK12,13 and the ZINC15 database of virtual compounds14 to identify possible 
compounds that may interact with the allosteric pocket of PGAM5. Various iterations of DOCK 
exist, the original established in the Kuntz lab in the early 1980’s at UCSF15, which later 
segmented, and two branches are current in development: DOCK 6.9 and DOCK3.7.  DOCK3.7, 
optimized from DOCK 3 branch and currently developed in the Shoichet lab, was used to identify 
and test preliminary potential ligand candidates to PGAM5’s allosteric pocket. To perform a 
virtual screen with DOCK3.7 for PGAM5, we first performed the preliminary ligand and receptor 
preparation steps followed by orienting and scoring as outlined in the following. 
Ligand preparation. To prepare the ligands for sampling, the internal degrees of freedom as 
measured by the rotatable bonds and torsion angles for each must were identified and pre-
computed prior to introduction of the ligand to the receptor. The conformational sampling was 
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generated about an unvarying part of the ligand, most often a ring, creating a hierarchy.  Up to 
three hierarchies, in the form of three rings, were generated for each molecule.   
Receptor Preparation.  In order to prepare the receptor for ligand binding simulations, we selected 
a binding site of interest and used hotspots in the shapes of spheres to define the binding site of 
interest. These spheres were generated by combining a crystallographic ligand with spheres that 
defined the inverse image of the pocket, which in turn was generated with Sphgen. To generate 
potential modifiers of PGAM5, we used the side chains of residues Trp58, Trp62, Asp43 and 
Arg65 of the multimerization motif rather than the backbone to define the pocket for 6CNL. To 
define the pocket of the 3MXO structure, we similarly relied on use of side chain residues, in this 
case using Met89 and Tyr92, which overlap with the multimerization motif binding site. Missing 
regions for 3MXO were added with Modeller and AMBER to minimize the model, while 
crystallographic coordinates were unmodified for 6CNL. After we defined the pocket of interest, 
we generated energetic grids about the spheres to define the bounding box by pre-computing the 
energetic properties of the binding site. These energetic grids were generated by placing a dummy 
atom at each grid point and subsequently calculating the energetics between that dummy atom 
with the whole receptor protein. Use of the pre-computed grids allowed for more rapid evaluation 
of energies during docking. By using grids to precompute the energies, we were able to 
substantially speed up our scoring calculations within the docking program. Three different grids 
were used to generate Van der Waals, electrostatic and ligand desolvation grids. Van der Waals 
and ligand desolvation grids were generated with the dock accessory programs ChemGrid and 
SolvMap, respectively, while the electrostatics grid was generated with Qnifft. Once the receptors 
were prepared, we moved on to orientation and scoring of possible modifiers of PGAM5.  
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Orienting and scoring.  Orientation sampling and scoring were performed within the DOCK3.7 
program. We used DOCK3.7 to first identify possible matches between atoms of the unvarying 
part of the ligand and the spheres by comparing their internal distances. Using this technique, many 
possible matches were generated. DOCK3.7 then subsequently oriented potential matches by 
orienting the unvarying segment of the ligand into the receptor binding site, placing the matched 
atoms onto the matched spheres, along with the rest of the ligand hierarchy. The orienting step was 
performed for all viable matches; multiple orientations were generated for each hierarchy. Scores 
for all orientations and conformations of the potential ligand were then calculated on the 
precomputed grid. Generation of this score served as a crude approximation of binding energy and 
was made up of three different terms: Van der Waals, electrostatic and ligand desolvation. The 
Van der Waals term served to highlight shape complementarity as well as quality of fit, the 
electrostatic term served to estimate charge complementarity while ligand desolvation represented 
the cost of displacing waters from the ligand. Overall, this generated score was used to select the 
best poses for each ligand and generate a rank for the possible candidate molecules. The molecules 
with the best scores were selected for further analysis.  
By using these techniques, we performed virtual screens against PGAM5 to identify 
candidate molecules that may be able to interact with PGAM5’s allosteric pocket for experimental 
testing. Two different PGAM5 structures were prepared and four docking calculations were run. 
Our dodecameric active structure (PDB: 6CNL) and the pre-existing inactive dimer (PDB: 3MXO) 
structure were both prepared for docking using the above technique. The ZINC15 database, 
containing 169 million lead-like molecules and 11.5 million fragments, was screened. Four initial 
docking calculations were performed: for both PGAM5 structures, we docked both lead-like 
molecules and fragments to the allosteric pocket.   
 85 
For each screen, to group chemotypes together, the top 300,000 molecules were clustered using 
ecfp4 fingerprints in Chemaxon, Tc calculations and a best first clustering scheme to narrow down 
the list of possible candidate molecules. The top 1000 cluster heads were then subsequently 
visualized in the context of the receptor using the ViewDock module in UCSF Chimera. Candidate 
molecules were eliminated through visual inspection for the following reasons: (1) the molecule 
existed in an unreasonable protomer or tautomer, (2) the molecule had internal strain in the form 
of internal clashes or odd geometry, (3) the molecule had one or more stranded hydrogen bond 
donor, (4) the molecule had two or more stranded hydrogen bond acceptors. In addition to these 
inspection guidelines, (5) the molecule’s quality of fit and (6) the molecule’s quality of polar 
interactions in the form of hydrogen bonding were also evaluated for in selecting the top candidates 
for possible PGAM5 modulation.   
The best 17-23 molecules from each of the screens were presented in a hit picking party 
and assigned a grade by five experts from the Shoichet lab to narrow down the list of possible 
candidates to the 30 most promising molecules. These molecules where ordered from Enamine for 
make-on-demand synthesis. Of these 30, two were unable to be synthesized, leaving 28 candidates 
to test for binding to PGAM5 (Fig. 3.2). The initial 28 compounds were a combination of 
fragments and lead-like molecules and were tested in their ability to modulate PGAM5’s 
phosphatase activity and ability to form higher order structures.   
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Figure 3.2: 28 potential PGAM5 compounds. Combination of fragment and lead-like 
compounds acquired from Enamine based on their potential to bind to and modulate PGAM5’s 
activity and ability to form higher order structures.  
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Effect of compound on different oligomeric states of PGAM5 
Now that we had identified potential modulators of PGAM5, we began by testing their 
activity towards purified Δ48 PGAM5. To saturate the protein and attempt to disrupt any 
previously bound multimerization motif bound in the allosteric pocket, we incubated 20 nM final 
concentration of purified protein with 1 mM of compound. Each activity assay was initiated with 
the addition of 75 μM final concentration of pASK1 substrate peptide. Quenching and subsequent 
detection of the free phosphatase in solution was followed by normalization of the observed 
activities relative to the negative control Δ48 WT incubated with DMSO and tested with pASK1 
peptide. Preliminary experiments indicate that four of the compounds generated had an effect on 
phosphatase activity. Compounds 13, 19, 22, and 28 resulted in a 25% decrease in phosphatase 
activity and appeared the most promising compounds to pursue in further studies (Fig. 3.3).  
 
Figure 3.3: Activity of Δ48 PGAM5 incubated with compounds for pASK1 substrate. 20nM 
Δ48 PGAM5 incubated with 1mM compound, followed by exposure to 75 μM pASK1 substrate 
peptide. Activity normalized for phosphatase activity of Δ48 in the presence of DMSO for pASK1.  
 
Curious to more rigorously parse filamented from dimeric protein, we repeated this 
experiment immediately after size exclusion purification of Δ48 PGAM5. Freshly collected peak 
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maxima from the filamented and dimeric peaks were incubated with 1 mM compound and tested 
for phosphatase activity against substrate 75 μM final concentration of pASK1 substrate peptide 
(Fig. 4). Similar to earlier experiments, compounds 13, 19, 22 and 28 showed a consistent decrease 
in phosphatase activity, though the exact effect they had on filaments or dimeric protein was 
varied. Significantly more variation in the effect of the compounds on dimeric PGAM5 was 
observed, which may have been contributed to by our earlier observation that the dimeric peak of 
Δ48 PGAM5 is able to spontaneously dodecamerize and are able to subsequently form filaments 
in solution, which may affect the compound’s ability to interact with PGAM5 at the target 
allosteric pocket of interest.  
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Figure 3.4: Activity assays of filamented or dimeric PGAM5 in the presence of compounds. 
Phosphatase activity assays of filament peak (upper panel) and dimeric peak (lower panel) 20nM 
Δ48 PGAM5 for 7μM pASK1 peptide after incubation with 1 mM of each of the compounds.  
 
Given the tight interaction between the multimerization motif and the allosteric pocket of 
PGAM5, we were curious if the binding affinity between the compounds and the allosteric pocket 
might be too weak to dislodge any previously bound multimerization motif. To spatially separate 
the multimerization motif from the phosphatase domain, we opted to set up a competition assay in 
which we incubated the purified Δ90 catalytic core of PGAM5 with the compounds, followed by 
subsequent addition of the multimerization motif peptide added in trans. Previous assays have 
indicated Δ90 PGAM5 alone has poor catalytic activity on the order of hours; given this 
consideration, we incubated the phosphatase reaction for three hours at room temperature. 
Quenching and subsequent detection of the free phosphatase in solution followed by normalization 
of the observed activities relative to the negative control Δ90 WT incubated with DMSO, 
incubated with the multimerization motif and subsequently and tested with pASK1 peptide 
indicates that the majority of the compounds had an effect on phosphatase activity (Fig. 3.5). The 
decrease in phosphatase activity observed compared to the filamented form of the protein suggests 
that the compound’s inability to better inhibit phosphatase activity may be due to its inability to 
access the allosteric pocket in the presence of a pre-bound multimerization motif.  
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Figure 3.5: Effect of compounds on activity of Δ 90 PGAM5.  500nM Δ90 PGAM5 incubated 
with 1mM compound, followed by incubation with 20uM multimerization motif and subsequent 
exposure to 75uM pASK1 peptide. 
 
Dose response of best hits 
Given that we do not know the oligomeric state of PGAM5 while on the mitochondrial membrane, 
or if the multimerization motif is able to interact with the catalytic core while membrane tethered, 
we became most interested in further exploring the compounds that show most potent effect on 
filamented PGAM5, as these most likely possessed the highest binding affinity for the protein. 
Cross comparison of the effect of the 28 compounds on PGAM5’s phosphatase activity led us to 
decide to focus on compounds 13, 19, and 22, as these consistently showed consistent phosphatase 
activity inhibition in the presence of the multimerization motif containing construct. We decided 
to perform a dose response of compound 3, one with which we had seen no real change on 
PGAM5’s activity as a phosphatase, in parallel as a negative control. In order to begin to determine 
the range of inhibition of the compounds of interest for PGAM5 and their maximal inhibitory 
effect, we performed a dose response experiment in which we varied the concentration of 
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compound while maintaining the concentration of Δ48 WT protein constant (Fig. 3.6). Based on 
our dose response data, we were able determine for efficient binding and inhibition of PGAM5, 
we would require concentrations higher than 1mM of compound for our crystallography and future 
activity assays. This proved challenging, especially given some difficulty we observed with 
compound precipitation, particularly with compound 22, which we observed readily precipitates 
out of solution at concentrations higher than 1mM. Despite this, we were able to determine binding 
of compound binding to PGAM5 is weak and suggested our follow up crystallographic and activity 
assays would require high concentrations of compound to bind to and inhibit PGAM5.  
 
 
Figure 3.6: Dose response of Δ 48 PGAM5 for compounds of interest. 20nM Δ48 PGAM5 was 
incubated with a range of compounds 3, 13, 19 or 22 ranging from 0-4mM (upper left, upper right, 
lower left, lower right, respectively). Data for compound 22 higher than 1mM excluded due to 
precipitation.  
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Compound specificity for PGAM5  
One concern with initial trials of compounds on receptor activity is that these novel 
compounds may aggregate, causing receptor aggregation and an artificial, non-specific decrease 
in target protein activity. To validate the specificity of the compounds of interest for PGAM5 in 
inhibiting its phosphatase activity, we tested whether the most promising compounds would inhibit 
activity of an unrelated protein. We incubated BMPR2 kinase with 1mM of compounds 13, 19 and 
22 and observed these compounds show no significant effect on the kinase’s activity. The lack 
interference of BMPR2’s kinase activity in the presence of 1mM of each of the compounds as 
compared to a DMSO control indicates the ability of these compounds to inhibit PGAM5 is 
specific an is not merely due to compound-directed protein aggregation (Fig. 3.7). Now that we 
were able to determine the interaction these compounds have with PGAM5 is specific, we pursued 
a high-resolution structure of the interaction of our PGAM5 protein with these novel compounds.  
 
Figure 3.7: Compound specificity for PGAM5. Validating specificity of compound inhibition 
for PGAM5 through a phosphatase assay (left) compared to kinase assay for BMPR2 done in 
presence of BMPR2 kinase pre-incubated with compounds (right).  
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Crystallization of Δ90 PGAM5 in presence of most promising compounds 
Identification and preliminary testing of the possible compounds suggests that these 
compounds are able to specifically inhibit PGAM5’s phosphatase activity. In an effort to verify 
the site of interaction of these compounds with PGAM5, we sought to solve a crystal structure of 
the catalytic core of PGAM5 with compounds 13, 19 or 22.  
Our initial crystallographic attempts focused on soaking existing Δ90 H105A and Δ90 WT 
PGAM5 crystals with serial dilutions of the compounds (Fig. 3.8). We generated crystals for 
PGAM5 in identical conditions to our Δ90 H105A structure (PDB: 6NCI) and first attempted to 
bind compound to protein by incubating our protein crystals in the presence of  compounds 13, 19 
and 22. Given that our crystals appeared stable in the presence of compound for multiple days and 
up to a week, we proceeded with data collection. Using molecular replacement, we were able to 
solve the structure of Δ90 PGAM5 but were dismayed to find a lack of density for each of the 
compounds in the allosteric pocket. Analysis of the electron density revealed that rather than 
having compound bound in the allosteric pocket, the N-terminal scar resulting from the TEV 
cleavage of the 6xHIS tag at the N-terminus of our construct occluded the predicted compound 
binding site. We were unable to observe any corresponding to compound bound to PGAM5 for in 
any of these crystal structures.  
 Our subsequent attempts focused on co-crystallizing Δ90 H105A WT PGAM5 with 
compounds. To this end, we incubated the protein with 2.5mM of each compound, centrifuged to 
remove any excess precipitant and crystallized in earlier MgCl2, HEPES and PEG solution found 
to yield abundant crystals and crystallized in hanging drop. Our observation that PGAM5 was able 
to crystallize in the presence of compound left us hopeful that the protein had succeeded in 
interacting with compound and we proceeded with data collection and processing. Despite having 
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crystallized the protein in the presence of each of the compounds, we found that all of the structures 
we solved lacked density for any of the compounds, and instead observed the N-terminal TEV-
cleave site methionine overhang once again occupied the region of interest. In an effort to relieve 
this potential overhang and leave the region of interest exposed for compound to interact with and 
have the ability to bind in PGAM5’s allosteric pocket, we decided to modify our crystallographic 
construct.  
 
Optimization and purification of 3x-GS linker-Δ94 PGAM5 
Due to our identification of the N-terminus TEV scarring site in the allosteric pocket of 
PGAM5, we decided to generate various constructs of PGAM5 that would eliminate the N-
terminal’s association with the region of interest. Cleavage of our N-terminal 6x-HIS tag resulted 
in a methionine overhang, which interacted consistently with the region of interest. In an effort to 
eliminate this interacted, we proceeded to generate a construct with a singular patch of GS residues 
immediately following the 6x-HIS tag. Additionally, we generated a construct with a repeating 3x-
GS linker immediately after the 6x-HIS tag.  
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Figure 3.8: Crystallographic attempts with PGAM5 and compounds. a. Soaked Δ94 H105A 
PGAM5 crystals in compounds 13 and 19. b. Co-crystallization of Δ94 H105A PGAM5 with 
compounds 19 and 22. c. Two views of PGAM5’s allosteric pocket showing electron density for 
Δ94 H105A PGAM5 co-crystallized with compound 13. Green mesh indicates observed region of 
density for overhang methionine in lieu of compound density. 
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3.3 DISCUSSION 
 
While phosphatases have remained largely understudied, the critical roles they play in the 
cell through their ability to post-translationally modify substrates and directly affect cellular 
outcomes make them an important region of study. PGAM5’s emergence as a regulator of cellular 
life and death, as well as a novel signaling node implicated in vastly different functions within the 
mitochondria, presents this atypical phosphatase as a fascinating subject of study. Its novel mode 
of self-regulation and complex higher order structure make it a compelling yet challenging 
potential drug target.  
In collaboration with the Shoichet lab at UCSF, we have identified and characterized 28 
possible novel regulators of PGAM5’s phosphatase activity and have performed preliminary 
analyses on their ability to interact with the phosphatase to modulate its phosphatase activity. We 
have parsed these compounds by their ability to interact with the catalytic core of PGAM5 through 
interactions with Δ90 PGAM5 and their ability to bind to and inhibit Δ48 PGAM5 as a dimer or 
filament. We have identified three compound candidates which we believe would be of interest to 
optimize and pursue further through biochemical, cellular and structural means.   
Finding a way to tightly control PGAM5’s ability to self-associate and self-activate would 
be of therapeutic value and would yield a great new tool through which to control various 
mitochondrial pathways and cell life or death. Our work has provided new structural insights 
behind the mechanism of PGAM5’s activation as a phosphatase, but much remains unknown about 
this peculiar phosphatase and the ways in which it controls cellular outcomes. It remains a 
possibility that PGAM5’s interaction with its wide variety of protein binding partners and its 
ability to function as a signaling node between mitochondrial homeostasis or cell death could be 
regulated by its multimeric state. 
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Following the conclusion of these experiments, it has been observed PGAM5’s dynamic 
multimers are able to dephosphorylate BCL-xL or FUNDC1, and in doing so, effectively regulate 
mitochondrial and cellular fate16. Dephosphorylation of BCL-xL by dimeric PGAM5 has been 
found to result in anti-apoptotic activity, while it was found that under induced oxidative stress 
conditions, the amount of multimerized PGAM5 increases and results in dephosphorylation of 
FUNDC1. Dissociation of PGAM5 from BCL-xL and association with FUNDC1 has been 
observed to result in mitochondrial fission and mitophagy, putting forth the idea that PGAM5 is 
able to function as a sensor for oxidative stress and respond by changing its oligomerization state, 
substrates, and thereby regulate mitochondrial integrity and morphology. Ultimately, it is 
postulated PGAM5’s oligomeric state may be able to determine whether the cell will live or die. 
These new and exciting results shed light on the importance of designing, testing and optimizing 
small molecule inhibitors of PGAM5, a feat which our laboratory will continue to pursue. 
Additional work is needed to further optimize, characterize and improve the ability of these 
preliminary compound hits for PGAM5, but will yield great tools to further study this fascinating 
atypical protein phosphatase.  
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3.4 METHODS 
Protein expression and purification: Wild type full-length PGAM5 cDNA (corresponding to the 
PGAM5 long isoform (PGAM5L), residues 1-289) was purchased from Addgene. For bacterial 
expression and purification, the ∆90 PGAM5 (residues 91-289) and Δ48 PGAM5 (residues 49-
289) were cloned into the pET28a expression vector (Novagen). These constructs were N-
terminally tagged with hexahistidine (6X-HIS) followed by a linker sequence encoding a TEV 
protease cleavage site (ENLYFQS). Addition of a GS-linker was added (3x-GS) for additional 
crystallographic experiments by adding GSGSGS sequence between the N-terminal 6X-HIS and 
TEV sites and residue 95 of PGAM5 (3xGS-∆94 PGAM5). Mutations were introduced using either 
QuickChange mutagenesis or through Gibson assembly17. Primers used for mutagenesis are as 
follows: H105A (Forward: 5’-acatcttcctcatcagggcttcccagtaccacgtgg-3’ Reverse: 5’-
ccacgtggtactgggaagccctgatgaggaagatgt-3’), Y198E (F: 5’-gctccgtcttcctcatactgcacagcttccggc-3’ R: 
5’-gccggaagctgtgcagtatgaggaagacggagc-3’), R65A (F: 5’-agagacagtggttctgccctgtcccagttggg-3’ R: 
5’-cccaactgggacagggcagaaccactgtctct-3’), F244E (F: 5’-gccagccttcaggaggctcctgcagtgctctgcac-3’ 
R: 5’-gtgcagagcactgcaggagcctcctgaaggctggc-3’), R288E (F: 5’-
cctcccgacaagatcactgaatcctgagatccgaattc-3’ R: 5’-gaattcggatctcaggattcagtgatcttgtcgggagg-3’). 
Mutation of WT A4 was done by sequential mutation of W58A and D59A and followed by W62A 
and D63A. W58A/D59A (F: 5’- gtcccagttgggggccgcgacaccggggccc-3’ R: 5’- 
gggccccggtgtcgcggcccccaactgggac-3’), W62A/D63A (F: 5’- gtggttctcgcctggccgcgttggggtcccaga-
3’ R: 5’- tctgggaccccaacgcggccaggcgagaaccac-3’). 
For recombinant protein expression, BL21 DE3 pLysS E. coli cells transformed with 
pET28a-PGAM5 constructs were cultured in Luria Broth media supplemented with kanamycin 
(30 µg/mL) at 37o C until 0.4 optical density at 600 nm was reached. Protein expression was 
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induced with 0.2 mM IPTG and cells were cultured for additional 12 hours at 25o C. Following 
collection by centrifugation at 5000 x g, cell pellets were resuspended in Lysis Buffer (20 mM 
Tris-Cl pH 8.0, 500 mM NaCl, 0.5 mM TCEP, 5% glycerol, 20 mM Imidazole pH 8.0 
supplemented with EDTA-free protease inhibitors (Roche)). Cells were lysed by sonication at 25% 
of max power in cycles of 4s on and 2s off for 5 minutes. Lysates were clarified by centrifugation 
at 18,000 x g and loaded by gravity flow on HiTrap Ni-NTA resin (GE Healthcare). Protein was 
eluted using Elution Buffer (20 mM Tris-Cl pH 8.0, 500 mM NaCl, 0.5 mM TCEP, 5% glycerol, 
200 mM Imidazole pH 8.0) and exchanged into buffer containing 20 mM Tris-Cl pH 8.0, 150 mM 
NaCl, and 0.5 mM TCEP using a 10 kDa cutoff concentrator (Millipore). The sample was further 
purified by size exclusion chromatography (SEC) using a Superose 6 10/300 GL Increase column 
(GE Healthcare) equilibrated in buffer containing 20 mM Tris-Cl pH 8.0, 150 mM NaCl and 0.5 
mM TCEP. Fractions were collected and used immediately for activity assays or to set 
crystallography trays.  
 
PGAM5 expression in Jurkat cells: Wild type full-length PGAM5 cDNA (corresponding to the 
PGAM5 long isoform (PGAM5L), residues 1-289) was purchased from Addgene. For expression 
in Jurkat cells, full-length and ∆2-24 (residues 24-289) PGAM5 variants for mammalian cell 
expression and imaging were cloned into the pIRES2 vector (Invitrogen). Jurkat cells were 
acquired from J. McLaurin in the Weiner lab at UCSF. Cells were transfected with pIRES2 vectors 
using Trans-IT Jurkat transfecting reagent (Mirusbio Cat # MIR2120) following recommended 
manufacturer protocols.  
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Modeling: Docking for the allosteric pocket of PGAM5 with lead-like molecules and fragments 
was performed using DOCK3.7 by Trent Balius, PhD. DOCK3.7 is freely available for non-
commercial research (http://dock.compbio.ucsf.edu/DOCK3.7/).Compounds docked in this study 
are freely available on the Irwin and Shoichet lab lead-like make on demand library 
(http://zinc15.docking.org/). Compounds were purchased from Enamine, Kiev, Ukraine.  
Chemaxon was used to protonate ligands, Corina was used to generate the initial 3D conformation, 
AMSOL used to calculate partial charges and desolvation values, Omega from OpenEye was used 
to conformationally expand ligands and mol2todb2.py was used to generate the dockable db2.gz 
files from output from the previous steps. The above steps were run through the 
generate/build_database_ligand.sh script provided with the DOCK 3.7 distribution 
 
Compound acquisition, dilution and storage: Compounds were purchased from Enamine 
(https://enamine.net/) and were received as a mixture of viscous oils or powders. Compounds were 
dissolved in 100% fresh DMSO to make up 250 mM stocks and stored in glass vials with parafilm. 
Stocks were kept at -20 o C for long term storage. Aliquots were made to be used for experiments 
to avoid repetitive freeze-thawing of compounds. Compound ID, ZINC ID, molecular weight 
(MW) and logp values provided in table 2.1.  
 
Peptides: The ASK1 phosphopeptide (NFEDH(pS)APPSP) and the PGAM5 multimerization 
motif (MM) peptide (GPGVWDPNWDRREP)9 were purchased at a purity of 95% or greater (Elim 
Biopharma). Peptides were resuspended in 20 mM Tris-Cl pH 7.5, aliquoted, and flash frozen in 
liquid nitrogen prior to storage at -80o C.  
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Table 3.1: Enamine compound ID, ZINC ID, molecular weight and logp values 
Compound ID ZINC ID mwt logp 
1 Z1255564056 ZINC000121091067 248.311 1.925 
2 Z2772154651 ZINC000631611880 242.3 -0.314 
3 Z1177728516 ZINC000348868450 249.314 0.609 
4 Z1656071016 ZINC000182751233 239.34 1.112 
5 Z2285860826 ZINC000651254919 228.295 3.166 
6 Z2808669295 ZINC000636686801 330.381 0.693 
7 Z2496159919 ZINC000654585699 330.392 1.667 
8 Z1835946072 ZINC000188385791 243.31 1.669 
9 Z2160513701 ZINC000347306850 338.367 2.709 
10 Z1709214128 ZINC000575636852 351.428 1.294 
11 Z1183910699 ZINC000069798379 234.249 3.014 
12 Z813229004 ZINC000056557853 322.372 2.171 
13 Z1583451895 ZINC000091025924 296.374 3.218 
14 Z1686540422 ZINC000273841125 247.323 2.786 
15 Z2274656608 ZINC000450928572 239.269 2.294 
16 Z2069918626 ZINC000496476237 339.373 1.948 
17 Z2638697773 ZINC000614530974 249.285 1.631 
18 Z381616680 ZINC000047989063 241.294 2.311 
19 Z1618007411 ZINC000539806212 315.442 3.022 
20 Z1673501846 ZINC000170594968 245.311 2.106 
21 Z2044042936 ZINC000284152823 310.401 2.388 
22 Z2274654255 ZINC000382428661 222.719 2.615 
23 Z3252177877 ZINC000629359812 245.322 2.996 
24 Z1416609479 ZINC000675300140 296.374 2.449 
25 Z2840961144 ZINC000640249651 339.442 2.385 
26 Z2217546493 ZINC000292716812 248.373 1.553 
27 Z2721846482 ZINC000629359812 245.322 2.996 
28 Z1787490399 ZINC000094601543 268.32 2.393 
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Phosphatase activity assay: Phosphatase assays were performed at room temperature for wild 
type 6xHIS-∆48 PGAM5 and 6xHIS-∆90 PGAM5. Protein was diluted into reaction buffer to a 
final concentration of 20 nM and incubated with 1mM final concentration of each compound. 
DMSO was used as a negative control for each series of reactions, and each reaction was set up in 
triplicate. Protein was incubated in the presence of compound for 25-30 minutes at room 
temperature prior to addition of the substrate peptide. ASK1 phosphopeptide was diluted to 750 
μM into reaction buffer (20 mM Tris-Cl pH 8.0, 150 mM NaCl and 0.5 mM TCEP) and reaction 
was initiated by addition of substrate peptide to compound and protein incubation mixture. 
Reaction was run for 10 minutes at room temperature prior to quenching with R&D Malachite 
Green phosphate detection kit (Cat: DY996) following manufacturer protocol. The total free 
phosphatase in solution was measured as the absorbance at 620 nm. 
 
X-ray crystallography:  
Soaking of ∆90 H105A PGAM5 with compounds 13, 19 and 22: The ∆90 H105A PGAM5 
construct was crystallized using hanging drop vapor diffusion at room temperature in the absence 
of the ASK1 phosphopeptide. Crystals were grown in a 2 μL drop (1 μL protein reservoir solution) 
against a reservoir solution comprised of 100 mM HEPES pH 7.5, 200 mM MgCl2 and 30% w/v 
PEG 400. Once crystals were fully grown, crystals were soaked in 0-2.5mM of each of the 
compounds for 24-72 hours at room temperature. Crystals from both conditions were 
cryoprotected with Paratone-N oil and flash-cooled to 100 K in liquid nitrogen.  
 
Co-crystallization of ∆90 H105A PGAM5 with compounds 13, 19 and 22: Purified protein was 
concentrated to 10 mg ml-1 by centrifugation (Amicon Ultra-15, 10 kDa molecular mass cutoff; 
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Millipore). Initial attempts to combine purified recombinant ∆90 H105A with various 
concentrations of compounds between 0-2.5mM resulted in precipitation of protein in the drops 
but yielded protein crystals over 1 week. Crystals were cryoprotected with Paratone-N oil and 
flash-cooled to 100 K in liquid nitrogen. 
 
Data collection: X-ray diffraction data were collected at 1.111 Å, 77K at the ALS 8.3.1. beamline 
(Berkeley, CA) on a Pilatus 6M detector. Data were indexed with XDS18, scaled in Aimless19 and 
phases determined in Phaser20. ∆90 PGAM5 H105A crystals diffracted to 1.7 Å in space group 
P212121 and with unit cell dimensions: a = 71.0 Å, b = 72.0 Å, c = 81.9 Å, a = b = g = 90° and 
with two molecules in the asymmetric unit. A solution was generated by molecular replacement 
using one copy of PDB 3MXO as the search model. Refinement was performed in Phenix65 with 
iterative rounds of model building in Coot21. 
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